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Mefloquine-based chiral selectors and 
stationary phases (MFQ-CSPs) 
1. Introduction 
1.1 Mefloquine  
 
The most lethal human parasitic infection is still malaria. Millions of people die due to 
this disease every year worldwide, especially in Africa region. Therefore an effective 
treatment and malaria prevention is indispensable. The human malaria is caused by 
a parasite of the genus Plasmodium and it is mostly transferred by mosquitoes1. 
Mefloquine (MFQ) is one of the best known and most widely used antimalarial 
discovered during 1960s. Despite its side-effects such as dizziness, headache, 
insomnia, nightmares, severe depression etc.2,3, mefloquine is still used as an 
antimalarial drug because it is effective against resistant malaria species. Mefloquine 
is used as a suppressive prophylactic against malaria. That means that the drug is 
effective as long as the parasites are invading erythrocytes (red blood cells). 
However, in some regions, especially in Thai border areas, a mefloquine resistance 
has been observed. The mefloquine resistance is closely related to, the quinine 
resistance4.  
 
 
Figure 1: General structures of (9R,10S)-mefloquine hydrochloride (a) and (8S,9R)-quinine (b) 
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Since it is structurally an aminoethanol, mefloquine has been extensively tested also 
for different pharmacological activites, e.g. as cholinesterases inhibitor5, 
antituberculosis6, or antibacterial agent7. 
Synthetic mefloquine is a racemate8,9, the erythro isomers of α-(2-piperidinyl)-2,8-bis-
(trifluoromethyl)-4-quinolinemethanol; however, an asymmetric total synthesis of 
(9R,10S)-mefloquine has been published recently10. The structure of mefloquine is 
derived from cinchona alkaloids. The quinoline ring of mefloquine is substituted by 
two electron withdrawing groups instead of the electron donating methoxy group and 
the quinuclidine moiety of cinchonas is replaced by a less bulky piperidine ring. The 
absolute configuration of MFQ (+) and (-) enantiomers was assigned by comparing 
the circular dichroism spectra of (+)-MFQ and (-)-MFQ with those of (+)-QN and (-)-
QD11, the absolute configuration of those was confirmed by x-ray analysis12. 
Furthermore, it was found that the crystallographic structure of MFQ hydrochloride is 
similar to the crystal structures of QN and QD with respect to the quinoline moiety 
and the hydroxyl group. Also the distance between the aliphatic nitrogen and the 
hydroxyl group was found to be the same as in cinchona alkaloids13. Based on these 
similarities we decided to design and synthesize a new type of selector for chiral 
HPLC separation (see section 1.5 the aim of work). 
 
1.2 Chiral recognition 
 
Most of the natural products are chiral, e.g. sugars and amino acids. Chirality 
depends on the structural arrangement of the different substituents. A chiral 
compound cannot be converted to its mirror image by rotation. The mirror image of a 
chiral compound is called an enantiomer.  Many of the biochemical processes 
depend on chirality and therefore a lot of drugs are chiral. It is known that one 
enantiomer of a chiral compound achieves the desired effect of the drug (eutomer) 
and the other one can cause unwanted adverse effects (distomer). As a result it is 
necessary to have a separation technology, e.g. chromatography, to resolve the 
enantiomers of a racemic compound. 
The fact that enantiomers have the same physicochemical properties, except the 
optical rotation, makes them indistinguishable under achiral conditions. However, 
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there are certain analytical methods (chiral chromatography, NMR, etc.) that 
distinguish enantiomers directly. 
Therefore it is necessary to transform the enantiomers into diastereomers, which 
have distinguishable physicochemical properties. In chiral chromatography a 
distinction is drawn between indirect and direct enantiomer separation, according to 
the transformation mechanism of the enantiomer to the diastereomer14. 
 
The “indirect” approach means that the mixture of the to be separated enantiomers 
reacts with an enantiomerically pure chiral derivatizing agent (CDA) to form a pair of 
covalent bonded stereoisomers which are diastereomeric to each other and therefore 
separable with achiral chromatographic techniques15. For this approach it is 
necessary that the enantiomers contain a functional group, which allows a reaction 
with the chiral derivatizing agent. Furthermore it is indispensable that the chiral 
dervatizing agent is highly enantiomerically pure or at least the enantiomerical 
impurity is known. In case of enantiomerical impurities four stereoisomers will be 
formed whereby two pairs of them are enantiomeric to each other and therefore 
indistinguishable with achiral chromatographic techniques15. During derivatization 
racemisation of the enantiomer and the chiral derivatizing agent must be avoided, 
otherwise a mixture of stereoisomers will be obtained15 and quantification of the 
content of enantiomers in the sample will be impossible. 
The “direct” approach means that the enantiomers are reversibly converted to non-
covalent diastereomeric associates, which can be separated using chiral 
chromatographic techniques. The diastereomeric associates are formed by 
complexation of the enantiomers with an enantiomerically pure chiral auxiliary, which 
is often covalently linked to the surface of the stationary phase or added as additive 
to the mobile phase. In this approach a derivatization to create diastereomeres is not 
needed. The chiral auxiliary is often referred to as chiral selector15. 
Adding the selector to the mobile phase as additive and using an achiral stationary 
phase is termed as chiral mobile phase mode. The enantioseparation, and therefore 
a difference in elution times of the associates is caused by different adsorption 
strength of the diastereomeric associates on the stationary phase or by adsorption of 
the selector on the surface of the achiral stationary phase and binding the 
enantiomers with different energies15. Nowadays the chiral mobile phase mode has 
4 
 
limited practical importance in HPLC, because of the necessity to dissolve the chiral 
selector in the mobile phase, the influence of the selector concentration on the 
separation factor and so forth15. 
The use of an achiral mobile phase and an enantiomerically pure compound, the 
selector, covalently linked to the surface of a carrier material is termed the chiral 
stationary phase mode. The enantioseparation occurs due to the formation of a 
diasteromeric complex on the surface of the stationary phase between selectands 
and the selector. The selectands (enantiomers) have different affinity towards the 
selector and thus the complexes formed have diverse stabilities15. The separation of 
the enantiomers can be improved by varying the mobile phase conditions, like 
changing solvents, pH and additives or temperature. The classification of the chiral 
stationary phases depends on the used selectors. The following selector-types are 
used in chiral stationary phases: Polysaccharides, proteins, synthetic polymers, 
macrocyclic compounds, crown ethers, and selectors whose interactions are based 
on donor-acceptor principles or on ion-exchange principles. 
The basic concept of chiral recognition is the same for interactions between analytes 
and selectors, and interactions between chiral drugs and biological receptors. These 
association forces are of non-covalent nature, e.g. hydrogen-bonding, ionic 
interactions, π-π and dipole-dipole interactions as well as hydrophobic interactions 
14,15. The chiral recognition can be then explained by a three-point-rule16, which 
defines that at least three simultaneous interactions have to take place between the 
selector and the analyte for efficient separation of its enantiomers. The selectand 
exposes its binding sites to the surface of the stationary phase and if the interaction 
sites of the selector are suitably oriented in space, they can bind to the selector and 
an ideal fit is achieved. If less than three interactions are possible, then such a 
binding is called a non-ideal fit. The enantiomer, which achieves the ideal fit, is the 
stronger bound one, and thus elutes as the second peak the column15.  
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Figure 2: Schematical illustration of the 3-point rule 
Another fast and effective chiral recognition method is NMR. NMR itself is an achiral 
method and so it is necessary to transform the enantiomers in diastereomers with a 
chiral auxiliary. There are two ways in which the chiral auxiliary can be used for the 
formation of diastereomers respectively diastereomer associates, similar to the direct 
and indirect approach of chromatography. The chiral auxiliary can react with the 
enamtiomers prior to the NMR experiment in order to produce diastereomers or it is 
used as additive or solvent during the NMR experiments in order to form 
diastereomer associates which differ in chemical shifts according to the geometry 
and stability of the formed complexes17. In both cases the chiral auxiliary has to be 
enantiomerically pure and there should be no racemization during formation of 
distereomers. By the direct approach either a chiral solvating agent (CSA) or a 
paramagnetic chiral lanthanide shift reagent (LSR) is added to the solution of the 
sample as chiral auxiliary for the formation of diastereomer associates. The 
enantiomeric ratio and therefore the enantiomeric excess (ee) can be determined 
directly by comparing the integrals of the same functionality of the diastereomeric 
associates with different chemical shifts17. The chemical shift differences are usually 
small using chiral solvating agents for the formation of diastereomeric associates 
compared to the use of a paramagnetic chiral lanthanide shift reagent17. The 
chemical shift differences for the enantiomers are large when the functionality of the 
enantiomer which reacts with the LSR is close to the stereogenic centre of the 
analyte. The chemical shift differences are low for compounds which contain 
halogens or π -systems like aromatics17 when using of LSRs. 
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1.3 Chiral stationary phases (CSPs) for HPLC 
 
As previously mentioned a common method for enantiomer separation is the use of 
chiral stationary phases, where the selector is immobilized on a silica surface. 
Phases containing a selector with a low molecular weight are generally called brush 
type phases. A short overview of Pirkle phases (Donor-Acceptor-type CSPs) and 
ionic exchanger phases, which belong to the brush type phases, is presented in the 
following paragraphs. 
 
Donor-Acceptor-type CSPs (Pirkle phases): 
 
In Pirkle phases the chiral recognition is based on non-ionic attractive interactions, 
like hydrogen bonding, π-π -stacking, dipole-dipole- and sterical interactions14. Pirkle 
and coworkers developed the first commercially available CSP (DNBPG, Regis 
Technology) based on these interactions. This CSP was based on 3,5-dinitrobenzoyl-
phenylglycine, which was immobilized on modified silica. This selector and in general 
some types of donor-acceptor type-CSPs are based on low-molecular weight 
molecules and that allow immobilization with a high surface coverage. Additional 
advantages are good solubility and the possibility of structural modifications of this 
selectors14. Amines, amino acids, carboxylic acids, esters and ethers represent 
analytes whose enantiomers can be separated with a Pirkle phase18. These CSPs 
are usually operated in normal phase mode because in reversed-phase or polar 
organic phase mode the polar interactions (mostly hydrogen bonding) are diminished 
and the enantioselectivity of a Pirkle phase drops significantly14. 
 
Ion-exchange-type CSPs: 
 
The difference between Pirkle phases and ion-exchange type CSPs is that for the 
ion-exchange type CSP the main interaction is the long-range enantioselective ion-
pairing interaction between the complementary charged selector and the analyte 
species19,20. The ion-pairing interaction brings the analyte close to the selector and 
permits non-covalent interactions like π-π stacking, hydrogen bonding and steric 
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interactions. All these interactions cause the separation of enantiomers i.e., the 
discrimination of one enantiomer and its reduced retention19,20. These CSPs are 
usually operated in polar organic or reversed-phase mode15. A distinction is made 
between chiral anion exchanger and chiral cation exchanger corresponding to the 
charge of the analyte. Anion exchanger CSPs adopt a protonated form and are 
applicable for the enantio-separation of chiral acids, such as N-derivatized amino 
acids, peptides, aminosulfonic acids etc. On the other hand, cation exchangers CSPs 
represent a separation tool for chiral bases, e.g. chiral amines22,23,36. 
 A combination of both properties is realized within zwitterionic CSPs, where the 
selector consists of a protonated and an anionic part, and thus it is possible to 
separate zwitterions such as free amino acids. 
 
 
Figure 3: a: Anion exchanger CSP based on tBuCQN for the separation of chiral acids; b: Cation exchanger CSP based 
on linker acid derivatized with trans-2-aminocyclohexanesulfonic acid for the separation of chiral bases 
 
1.4 CSPs based on chinchona alkaloids 
 
In the workgroup of Professor Lindner many new selectors based on cinchona 
alkaloids have been developed and some of them have been 
commercialized21,22,23,24. 
The structure of a cinchona selector is based on π-basic quinoline ring which is 
connected via a hydroxymethylene spacer to the quinuclidine moiety. The strongly 
basic quinuclidine moiety is responsible for interactions with acidic groups, while the 
quinoline unit permits a  stacking with an aromatic part of the analytes. 
Quinine has been used as antimalarial drug and it has antipyretic properties. It was 
also used as uterotonics, because of the muscle relaxant effects. Due to its bitter 
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taste, quinine found the biggest application as an additive in tonic water. By UV 
irradiation of an acidic solution of quinine fluorescence can be observed. Quinidine is 
a pseudoenantiomer of quinine and has a reversed configuration on the C8 and C9 
position compared to quinine. It was frequently used as an antiarrythmic agent. Both 
quinine and quinidine and their derivatives are often employed as catalysts in 
stereoselective organic synthesis25.26 and as chiral solvating agents in NMR 
spectroscopy27,28. 
 
 
Figure 4: Cinchona alkaloids (8S,9R)-quinine (a) and (8R,9S)-quinidine (b) 
Quinine and quinidine can work as selectors immobilized through their double bond 
on mercatopropyl modified silica gel. Such CSPs can be employed in high-
performance liquid chromatography as weak chiral anion exchangers for 
enantioseparation of chiral acids. In this anion exchanger mode a buffered hydro-
organic mobile phase is used to obtain a positively charged nitrogen in the 
quinuclidine ring, which can interact with the negatively charged selectands29. 
Derivatization of the hydroxyl group located at C9 (see Figure 5) in the chinchona 
alkaloids quinine and quinidine can improve the chiral recognition for chiral acids, 
especially by introducing of a carbamoyl functionality29. Retention and 
enantioselectivity can be improved by optimization of the mobile phase conditions, 
like modifying the buffer concentration, the solvent composition, the pH and the 
temperature. 
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Figure 5: (8S,9R)-tBuCQN and (8R,9S)-tBuCQD 
Another type of chiral stationary phase developed in Professor Lindner`s research 
group is a zwitterionic CSP (ZWIX CSP). This chiral stationary phase combines ion-
exchange principles of QN/QD-based anion exchanger and trans-2-
aminocyclohexanesulfonic acid-based cation exchanger. This type of selector was 
designed for the separation of a wide spectrum of chiral compounds. It can be used 
for separation of chiral acids, chiral bases and chiral amphoteric compounds like 
amino acids. The zwitterionic CSP is again applicable mainly for polar organic mobile 
phases15,24. 
 
Figure 6: Zwitterionic exchanger-type CSP based on quinine derivatized with trans-2-aminocyclohexanesulfonic acid 
for the separation of chiral acids, chiral bases and zwitterionic compounds 
The elution order of chiral acidic analytes obtained with the ZWIX CSPs (Figure 6) 
can be reversed by changing to the CSP of opposite configuration. This corresponds 
to the behaviour of the parent anion exchanger CSP based on quinine and quinidine. 
It was identified that the chiral recognition mechanism of chiral acidic analytes 
measured with this ZWIX CSPs is similar to the one of the parent anion exchanger 
based on quinine or quinidine. As a result it was observed that the attached trans-2-
aminocyclohexanesulfonic acid causes reduced run times compared to the parent 
anion exchangers. This means that the chiral recognition for acidic analytes depends 
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on the AX site and the CX site represented by the sulfonic acid acts as intermolecular 
counter ion23.  
For basic chiral analytes similar behaviour was observed. Enantioselectivity 
corresponds to the selectivity of the parent SCX based on trans-2-
aminocyclohexanesulfonic acid. The retention is reduced because of the 
intermolecular counter ion activity of the quinine/quinidine scaffold. The elution order 
of the basic analytes observed with the ZWIX CSP (Figure 6) cannot be reversed by 
changing the configuration of the trans-2 aminocyclohexanesulfonic acid. This 
indicates that the chiral recognition for basic analytes depends on the chiral 
environment of the quinine/quinidine scaffold and the trans-2-
aminocyclohexanesulfonic acid has only secondary influence23.  
Also amphoteric analytes, like amino acids, can be effectively separated using a 
ZWIX column (see Figure 6). The elution order is not reversed by using the opposite 
configuration of the trans-2-aminocyclohexanesulfonic acid part of the selector. This 
indicates that the elution order depends on the absolute configuration of the used 
chinchona-moiety. Therefore by changing the AX unit from quinine to quinidine, the 
elution order of amphoteric, acidic as well as basic analytes can be reversed23. 
 
The structure of mefloquine (see Figure 1) is closely related to the structure of 
cinchona derivatives and therefore it is very promising for the development of novel 
chiral stationary phases. We assumed that the introduction of a -acidic quinoline unit 
(caused by electron drawing trifluoromethyl groups) would provide a pronounced  
stacking with -basic analytes. As many pharmaceutical substances are based on -
basic aromatic systems it is of interest having a selector with a π-acidic aromatic 
counterpart because such a property may lead to a better separation of enantiomers. 
Using mefloquine as a starting building block, we decided to mimic the structure of 9-
O-tert-butylcarbamoyl quinine (tBuCQN)29, which is commercially available from 
Chiral Technologies Europe as Chiralpak QN-AX. Such a selector should work as π- 
acidic anion exchanger. Moreover, mefloquine can be used for the development of 
zwitterionic CSP.   
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1.5 The aim of work 
 
A, Synthesis of enantiomerically pure N-allyl mefloquine  
Starting from racemic mefloquine we needed to introduce a functionality which allows 
us to immobilize the selector on the modified mercaptopropyl silica gel. This can be 
achieved by introduction of a double bond at either the hydroxyl or the secondary 
amino group. We decided to allylate the nitrogen in the piperidine ring. For effective 
chiral recognition it is necessary to immobilize the enantiomerically pure selector, and 
thus the racemic starting compound has to be separated into its enantiomers (2a, 
2b). Such compounds can be subsequently immobilized or further functionalized.   
 
 
Figure 7: Enantiomers of the (9R,10S)-N-allyl mefloquine (2a) and (9S,10R)-N-allyl mefloquine (2b) 
B, Synthesis of N-allyl mefloquine carbamate and evaluation of its properties 
For the synthesis of mefloquine-based anion exchangers (4a, 4b) we decided to use 
a well-established procedure that had been used for the preparation of 9O-tert-
butylcarbomyl quinine (QN-AX)29. 
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Figure 8: Novel chiral selectors based on mefloquine carbamates 
For testing efficiency of our mefloquine-based selector, we decided to carry out an 
NMR study, which should give us the first insight into molecular recognition 
properties of the new SO candidate. Furthermore, all immobilized selectors were 
tested on a wide spectrum of analytes using HPLC in polar organic mode. In order to 
test the contribution of π-acidic quinoline part of the new selector, specially designed 
selectands were prepared. 
C, Synthesis of novel cation exchanger CSP  
In addition to the anion exchanger we decided to develop a novel cation exchanger 
based on O-allyl syringic acid derivatized with trans-2-aminocyclohexane-sulfonic 
acid (9a, 9b), which shall allow an efficient separation of mefloquine derivatives. The 
derivatized O-allyl syringic acid is a π-base and therefore an effective π-π stacking 
should be possible. Furthermore it represents a strong acid, which protonates tertiary 
amines and consequently also the nitrogen of the selector.  
 
Figure 9: Novel cSCX- CSPs 
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2. Synthesis 
 
As it was mentioned in the introduction, the main aim of the thesis was to prepare a 
mefloquine-based analogue of commercially available QN-AX and QD-AX columns. 
In order to mimic the structure of respective CSPs we decided to synthesize N-allyl 
mefloquine, which should be immobilizable through its double bond on 
mercaptopropyl-modified silica gel. 
 
2.1 Synthesis of the starting compound: N-allyl mefloquine 
 
The easiest way to synthesize tertiary amines out of secondary amines is to employ 
the Eschweiler Clarke reaction30. We decided to use a modified method31, where 
sodium cyanoborohydride is used as a source of hydride ion (Scheme 1). 
 
 
Scheme 1: Synthesis of N-allyl mefloquine using acrolein 
Previous results with formaldehyde proved the applicability of this method for the N-
alkylation of mefloquine. However, acrolein turned out not to be suitable for allylation 
of compound 1. The performed LC-MS analysis showed a complex mixture of 
compounds among which the desired product was not identified. It seems that the 
reactivity of acrolein is too high under given conditions and rather a kind of 
oligomerization is preferred instead of N-allylation. 
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Consequently, we decided to use a procedure for N-alkylation of mefloquine, which 
was recently described in the literature6. 
 
 
Scheme 2:  N-allylation of the mefloquine hydrochloride with allyl bromide and the synthesis of the N-allyl mefloquine 
hydrochloride 
At first, the commercially available mefloquine hydrochloride (1) was transformed into 
a free base with K2CO3, otherwise the nucleophilic substitution would not work. The 
nucleophilic weaker oxygen is not allylated in this way and selectively N-allyl 
mefloquine was formed. This reaction was very straightforward and also the work-up 
of the reaction mixture was elegant because the mixture was only diluted with water 
and the precipitated product was simply filtered. 
The molecular mass of the target compound (2) was checked by LC-MS; however, 
we were not successful in interpretation of NMR spectra. This was caused by high 
complexity of the proton spectrum and badly distinguished signals in its aliphatic part. 
Moreover, signals of the piperidine moiety in 13C NMR were completely missing. We 
assumed that such originally not expected behaviour could be caused by the high 
flexibility of the piperidine ring. As a result we decided to prepare the N-allyl 
mefloquine hydrochloride with a methanolic solution of hydrogen chloride (see 
Scheme 2). We anticipated that the salt should not be that flexible, because of the 
intramolecular hydrogen bonding between the hydrogen of the nitrogen with the 
chlorine atom, and the hydrogen of the hydroxyl group with chlorine as well. The 1H 
NMR spectra of compound 2c were actually more explicit and a full set of signals 
was obtained for 13C NMR. With the characterization of compound 2c we proved that 
the site-selective reaction led to the desired product. 
N
N
H
HO
CF3
CF3
Br
N
N
HO
CF3
CF3
K2CO3
(DMF)
HCl
+
1
2
C20H20F6N2O
Mol. Wt.: 418.38
C17H17ClF6N2O
Mol. Wt.: 414.77
C3H5Br
Mol. Wt.: 120.98
N
N
HO
CF3
CF3
H
Cl
2c
C20H21ClF6N2O
Mol. Wt.: 454.84
(MeOH)
HCl
15 
 
To further characterize compound 2 we separated the enantiomers using chiral 
HPLC. 
 
Figure 10: A mixture of mefloquine hydrochloride and N-allyl mefloquine (Stationary phase: Tau-QN (SW A11) 15 x 0.3 
cm, 3 µm; mobile phase: MeOH, 50 mM AcOH, 25 mM NH3; wavelength= 254 nm) 
 
Figure 10 shows an HPLC chromatogram of the racemic mixture of compound 1 the 
mefloquine hydrochloride (t3= 2.357 and t4=2.747 min) and 2 the N-allyl mefloquine 
(t1= 1.746 and t2=1.867 min), which was obtained when the reaction was terminated 
prematurely. Even if the reaction was complete according to TLC, it was necessary to 
crystallize the crude product from methanol in order to remove completely the educt. 
Figure 10 further shows that the elution order changes when the secondary amino 
group of the piperidine moiety of mefloquine hydrochloride is transformed into tertiary 
amino group. This behaviour is most probably caused by the change of the 
lipophilicity of the compound. 
 
For the CSPs based on mefloquine it was necessary to receive the enantiomerically 
pure compounds. Although we tried to modify our conditions in order to obtain better 
separation of the N-allyl mefloquine enantiomers using different columns and mobile 
phases, we were not successful to achieve α-values feasible for preparative 
separation. Therefore we decided to derivatize the N-allyl mefloquine with (O,O)-
diacetyl-(R,R)-tartaric acid anhydride (DATAAN), in the hope that the diastereomers 
would be separable via crystallization. 
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2.1.1 Synthesis of (R,R)-DATAAN 
 
 
Scheme 3: Synthesis of (O,O)-diacetyl-(R,R)-tartaric acid anhydride (DATAAN) starting from the (R,R)--tartaric acid 
 In the previous work, Professor Lindner had shown the applicability of 
enantioseparation of alkanolamines by derivatization with (R,R)-DATAAN and 
following separation of the diastereomers via crystallization32. As has already been 
mentioned, mefloquine is structurally an ethanolamine and thus we decided to use 
the same procedure. 
The synthesis of DATAAN (Scheme 3) is described in the literature33. (R,R)-tartaric 
acid, sulfuric acid and acetic anhydride were heated up for a few minutes. The 
reaction mixture was cooled with an ice bath, the precipitate was filtered and washed 
with dry benzene and stirred in absolute diethyl ether33. In this way, anhydride 5 was 
obtained as a white crystalline compound in a good yield. 
 
 
Scheme 4: Esterification of the N-allyl mefloquine with (O,O)-diacetyl-(R,R)-tartaric acid anhydride  
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Consequently mefloquine monotartrate 3 was prepared (Scheme 4). The reaction 
was carried out under an inert atmosphere of nitrogen, because DATAAN is very 
sensitive to air moisture and in the presence of water quickly hydrolyzes to the acid. 
The reactivity of DATAAN can be checked by simply dissolving it in dichloromethane. 
The reactive anhydride is soluble while the acid is insoluble. 
 
The separation of the diastereomeres with crystallization turned out to be not as easy 
as expected. We tried several solvents, like aceton, acetonitrile, ethanol, without and 
with additives like benzene, ethyl methyl keton and tert-butyl methyl ether. In the end 
we found out that it is possible to separate the diastereomeres with hot toluene, 
because one of them is soluble while the other is almost insoluble. However, it was 
necessary to wash the racemic precipitate several times with hot toluene and decant 
the solvent.  
Therefore we employed soxhlet extraction, which was more efficient. The racemic 
mixture was placed in a soxhlet extractor and continuously washed with hot toluene. 
After 6 h the crystals were removed from the soxhlet extractor, dissolved in a solution 
of tert-butyl methyl ether and ACN (2:3) and the solvent was evaporated. The solid 
was again placed in the extractor and the washing with hot toluene was repeated. In 
this way we were able to obtain the “insoluble” diastereoisomer as crystalline powder 
in >99% diastereomeric excess. The diastereomer soluble in toluene was obtained 
by evaporating the solvent. The course of the separation was observed using HPLC 
(Figure 11). 
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Figure 11: RP-HPLC chromatogram of N-allyl mefloquine (O,O)-diacetyl-(R,R)-tartaric esters after 6 h of soxhlet 
extraction (ratio 1:32; t1=1.576 and t2=2.154) (Mobile phase: 50% H2O, 0.1% FA; 50% ACN, 0.1% FA; Stationary phase: 
eclipse XDB-C18 5 µm 4.6 x 150 mm; wavelength =254 nm) (The signal at t = 5.514 corresponds to toluene.) 
 
Figure 11 shows the tartaric ester (t1=2.154. min) which is insoluble in toluene. This 
HPLC sample was taken from the residue in the soxhlet extractor after 6 h of 
extraction. To be certain that the other diastereomer was dissolved in the extraction 
solution an HPLC measurement was carried out as well. 
19 
 
 
Figure 12: RP-HPLC chromatogram of the soxhlet solution (Mobile phase: 50% H2O, 0.1% FA, 50% ACN, 0.1% FA 
Stationary phase: eclipse XDB-C18 5 µm, 4.6 x 150 mm; wavelength = 254 nm) 
 
Figure 12 shows that besides impurities the concentration of the first ester (t1=1.657 
min) is much higher than that of the second one (t2=2.180 min). In this way of 
separation of diasteroemers it is not unusual that one diastereomer is obtained totally 
pure and the second contains impurities of the first one. One has to find then a 
convenient method for purification of the second diasteroisomer. In our case we were 
able to find an optimal system for crystallization, and after a single crystallization from 
methanol we obtained the desired second diastereoisomer in a high purity (>99% 
de). 
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Figure 13: Synthesized diastereomeres by esterification with (R,R)-DATAAN 
It is necessary to hydrolyze each of the separated diastereomers to obtain 
entiomerically pure N-allyl mefloquine. The hydrolysis must not affect the absolute 
configuration of mefloquine, which may happen under strong basic conditions. 
Therefore we decided to use K2CO3 as a mild base32 (Scheme 5). The reaction 
control was done with TLC by comparing the reaction solution with corresponding 
standards (the tartaric ester and the N-allyl mefloquine). After several hours reaction 
time only the N-allyl mefloquine could be observed. The purification of the product 
was achieved with column chromatography (CH2Cl2/MeOH, 20:1). 
 
 
Scheme 5: Hydrolysis of the (9S,10R)-O,O-diacetyl-(R,R)-tartaric mefloquine monoester 
The obtained pure enatiomers of (9S,10R)-N-allyl mefloquine (2a) and (9R,10S)-N-
allyl mefloquine (2b) were the primary objective of the thesis. With these key 
compounds it was possible to proceed with immobilization for having a novel CSP 
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(see section 2.3) and these enantiomers were the starting compounds for the design 
of other selectors and CSPs. 
 
2.2 Preparation of carbamates based on (9S,10R)- and (9R,10S)-N-allyl 
mefloquine 
 
2.2.1 tert-butylcarbamoyl-N-allyl mefloquine (tBuCMFQ) 
 
As it has been mentioned above, the commercially available Chiralpak QN/QD-AX 
columns based on tBuCQN and tBuCQD selectors were the main motivation for the 
synthesis of the N-allyl mefloquine analogues. 
 
 
Scheme 6: Synthesis of the tBuCMFQ (the chiral bonding is undefined, but the carbamoylation was performed with the 
pure erythro enantiomers)  
Enantiomerically pure 2a or 2b reacted with tert-butyl isocyanate in a presence of 
dibutyltin dilaurate as a catalyst (Scheme 6). According to a standard operating 
procedure developed in our working group, the tBuCQN/tBuCQD started to 
crystallize immediately after pouring the reaction mixture into petrol ether. Therefore 
we decided to proceed with purification of the crude N-allyl mefloquine carbamate 4 
in the same way. Although we tried to cool down the resulting solution of the reaction 
mixture in petrol ether, no crystals appeared. Subsequently we employed also 
hexane as a less polar solvent but again no precipitate was formed. Therefore we 
used column chromatography for final purification of the product. To our surprise it 
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turned out that both the carbamates are highly viscous liquids and we were able to 
crystallize the (9S,10R) tBuCMFQ only after several weeks. 
 
2.2.2 3,5-Bis{trifluoromethyl}phenylcarbamoyl-N-allyl mefloquine (N-allyl-F-
CMFQ) 
 
We decided to synthesize the 3,5-Bis{trifluoromethyl}phenylcarbamoyl-N-allyl 
mefloquine because this compound should have more potent fluorophilic and π-π 
interaction sites than the tert-butylcarbamoyl derivatives 4. At first, we decided to use 
the same procedure as for the synthesis of tBuCMFQ in hot toluene with a tin 
catalyst (Scheme 7). 
 
 
Scheme 7:  Synthesis of the 3,5 bis{trifluoromethy}lphenylcarbamoyl-N-allyl mefloquine with (9S,10R)-N-allyl 
mefloquine in toluene 
In spite of purification with column chromatography the NMR showed a diversity of 
impurities and it was hard to identify the product. The failure of the reaction could be 
caused either by reaction conditions, i.e. decomposition of isocyanate because of 
high temperature (boiling toluene), or the isocyanate was already decomposed due 
to long storage. In order to avoid these problems, we decided to use a new batch of 
isocyanate and work at reduced temperature. 
Before we started this new experiment, we found a different reaction pathway in the 
literature, which was employed for the synthesis of a chinchona-based organic 
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catalyst34. This approach is based on the use of etheric solvent in which the catalyst 
is not needed. 
 
 
Scheme 8: Synthesis of 3,5-bis{trifluoromethyl}phenylcarbamoyl-N-allyl mefloquine with the (9R,10S)-N-allyl 
mefloquine in THF 
The reaction was carried out in freshly distilled and dried THF and therefore under 
nitrogen atmosphere (Scheme 8). The course of the reaction was monitored with 
TLC, and the pure product was obtained by double column chromatography. 
 
2.3 Immobilization of the mefloquine-based selectors 
 
The immobilization should have been with the pure enantiomers of N-allyl 
mefloquine. The standard operating procedure of the immobilization (Scheme 9) was 
developed in our working group35. However, it turned out that the coverage of the 
selector on silica gel was low using the standard conditions. 
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Scheme 9:  Immobilization of N-allyl mefloquine (the stereocenter is not specified, but the immobilization was carried 
out with the pure erythro enantiomers)  
Therefore we decided to perform a set of reactions with racemic N-allyl mefloquine 
using different reaction conditions and to save the enantiomerically pure compound 
for optimized immobilization. To improve the coverage, the amount of the radical 
starter was increased, the solvent amount was decreased and the reaction times 
were modified. It is known from previous experiments in our working group that the 
coverage of a selector on silica gel depends on the used amount of solvent, the less 
the better becomes the coverage. Moreover, the selector immobilized on silica gel is 
sensitive towards scratching. Therefore a certain carefulness is required by all 
mechanical manipulations like washing of the CSP, otherwise it can happen that the 
selector is removed. Although all these influences were considered and the handling 
with CSP was careful, the coverage was not improved. The coverage was 
determined by elemental analysis and the first estimation was done by comparing the 
selector weight in the washing solution with the amount used for immobilization. 
When the tare of the selector obtained by evaporation of the washing solutions was 
similar to the amount used for immobilization no elemental analysis was performed. 
 
Table 1: Optimization trials for the immobilization of mefloquine based selectors with 3 g of mercaptopropyl modified 
silica gel. 
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N
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OHAIBN
2a, 2b
selector [mg] MeOH [mL] AIBN [mol%] immobilization time  [h]
1 500 40 20 14
2 500 40 25 14
3 500 30 40 16
4 500 25 40 8
5 500 25 20 8
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For immobilization of N-allyl tBuCMFQ 500 mg of the selector per 3 g of 
mercaptopropyl modified silica gel, in 30 mL of MeOH with 20 mol% of AIBN was 
used. After 6 h immobilization time further 10 mg of AIBN were added to the 
immobilization suspension under increased nitrogen flow. The solution was stirred 
further for another 12 h. 
 
 
Scheme 10:  Immobilization of N-allyl mefloquine carbamate (the stereocenter is not specified, but the immobilization 
was done with the pure erythro enantiomer) 
 
2.4 Synthesis of the ZWIX CSP based on mefloquine  
 
One of the aims of the thesis was the synthesis of a zwitterionic chiral stationary 
phase based on mefloquine derivatized with trans-2-aminocyclohexanesulfonic acid. 
Such a CSP would be a π-acidic but also fluorophilic analogue to the known ZWIX 
phase based on quinine23. For the synthesis of the zwitterionic chiral stationary 
phase of quinine it is necessary to activate the starting compound with p-nitrophenyl 
chloroformate. Consequently, we decided to use this described procedure for 
mefloquine and employ p-nitrophenyl chloroformate as an activating group23. 
 
 
O Si
O Si
SH
(MeOH)
O Si
O Si
S
N
NF3C
CF3
O
O NH
N
N
O
CF3
CF3
O
H
N
AIBN
4a, 4b
26 
 
 
Scheme 11: Synthesis of the active ester of the racemic N-allyl mefloquine 
In case of QN or QD a quantitative yield of the active ester is usually obtained. 
Although a white precipitate was formed, NMR measurements revealed a complex 
mixture of products. The purification of the crude product with column 
chromatography afforded only p-nitophenol and mefloquine. 
Nevertheless, the synthesis of the carbamate with trans-aminocyclohexylsulfonic acid 
was tried. Therefore we decided to carry out the derivatization of protected trans-2-
aminosulfonic acid with the crude active ester. 
 
 
Scheme 12: Synthesis of a zwitterionic selector based on mefloquine 
The reactants were stirred for 3 days in dry DCM under nitrogen atmosphere. The 
course of the reaction was monitored with HPLC using a weak zwitterionic exchanger 
CSP. No change, i.e. formation of the product, during the reaction was found. 
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Because the synthesis of compound 7 through the activation with p-nitophenyl 
chloroformate did not work satisfactory, we decided to try an esterification with 
disuccinimidyl carbonate. We assumed that the formed activated ester 9 would react 
with the trans-2-aminocyclohexanesulfonic acid to, compound 7. 
 
 
Scheme 13: Synthesis of the NHS- ester with racemic N-allyl mefloquine 
However, even this way did not work. A possible solution could be the use of another 
catalyst or the reaction of mefloquine with the corresponding isocyanate of the trans-
aminocyclohexanesulfonic acid without the intermediate stage of the succinimide 
ester. 
 
2.5 Analysis of the elution order of N-allyl mefloquine enantiomers with 
HPLC 
 
The absolute configuration11 and the elution order of free mefloquine are well 
known23. However, modification of the basic site of the molecule can cause a subtle 
change in the nature of a compound and can lead to the reversal of the elution 
order23,29. Therefore we decided to derivatize quinine and quinidine, with diacetyl-
tartaric esters and compare the elution order of them with the one of the N-allyl 
mefloquine analogues. 
Surprisingly, the cinchona derivatives were in this case less reactive than mefloquine. 
A huge excess of the (O,O)-diacetyl-(R,R)-tartaric anhydride was needed for the 
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reaction (Scheme 14). However, the chromatograms showed that just a little amount 
reacted to the desired monoesters 11. There was also a possibility that the product 
partially hydrolyzed under the conditions of the HPLC measurement and therefore 
only a small amount of expected compound was detected. 
 
 
Scheme 14: Synthesis of the (8S,9R) quinine (O,O)-diacetyl-(R,R)-tartaric monoester, the same procedure was used for 
the derivatization of (8R,9S) quinidine 
Because the (R,R)-DATAAN approach was not successful, we decided to try the 
derivatization of the chinchona derivatives (Scheme 15) and N-allyl mefloquine 
(Scheme 16) with (O,O)-dibenzoyl-(R,R)-tartaric acid anhydride. We assumed that 
the so called DBTAAN would react slower but the stability of the resulting derivatives 
would be higher in comparison to (R,R)-DATAAN derivatives.  
The synthesis of the chinchona derivatives with DBTAAN showed better results 
(Scheme 15) than the esterification with (R,R)-DATAAN. Nevertheless, DBTAAN had 
to be added in excess15. Although a total conversion of the chinchona derivatives to 
the corresponding esters was not achieved, the amount of the esters was sufficient 
for the safe determination of the elution order. The reaction control was done with 
TLC; however, the product was not isolated and the reaction mixture was submitted 
directly to the HPLC measurement. 
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Scheme 15: Synthesis of the (8S,9R) quinine (O,O)-dibenzoyl-(R,R)-tartaric monoester, the same procedure was used 
for the derivatization of (8R,9S) quinidine 
N-Allyl mefloquine seems to react much better with both (R,R)-DATAAN and (R,R)-
DBTAAN in comparison to the chinchona derivatives (see analytical part, section 
assignment of elution order of mefloquine). The product was not isolated and it was 
directly submitted to HPLC measurements. 
 
 
Scheme 16: Reaction of the (O,O)-dibenzoyl-(R,R)-tartaric acid anhydride with (9R,10S)-N-allyl mefloquine, the same 
procedure was used for the derivatization of the (9S,10R)-N-allyl mefloquine 
 
2.6 Synthesis of analytical probes used for the evaluation of the 
mefloquine-based CSPs 
 
The novel mefloquine-based chiral stationary phases have been tested for their 
applicability toward enantioselective separation. For that purpose chiral analytes 
were necessary. Some of them were commercially available and some were 
N
O
N
N
O
N
O
O
O
OH
OBz
BzO
O
O
O
BzO
BzO
+ (dry DCM)
10 12
C20H24N2O2
Mol. Wt.: 324.42
C18H12O7
Mol. Wt.: 340.28
C38H36N2O9
Mol. Wt.: 664.70
HO
H H
9
8
9
8
N
NHO
CF3
CF3
O
O
O
BzO
BzO
N
NO
CF3
CF3
O
HO
O
OBz
OBz
(dry DCM)
2a,2b 13a,13b
C20H20F6N2O
Mol. Wt.: 418.38
C18H12O7
Mol. Wt.: 340.28
C38H32F6N2O8
Mol. Wt.: 758.66
H H
9
10
9
10
30 
 
synthesized by us. Especially analytes with a -basic aromatic system were of 
interest because of the assumed enhanced  interactions with -acidic but also 
fluorophilic quinoline ring of mefloquine. 
 
2.6.1 Derivatives of the 4-allyloxy-3,5-dichlorobenzoic acid 
 
SCX (16) CSP previously developed in our working group is based on 4-(allyloxy)-
3,5-dichlorobenzoic acid. It was found that mefloquine can be efficiently separated on 
this CSP36, and thus we supposed that the 4-(allyloxy)-3,5-dichlorobenzoic acid is a 
useful starting compound for the design of analytes for the evaluation of mefloquine-
based CSPs as well. 
Except for the described strong cation exchanger, we decided to prepare also a 
derivative of a proteinogenic amino acid. Hence we employed Steglich esterification 
of the 4-(allyloxy)-3,5-dichlorobenzoic acid with hydroxysuccinimide (Scheme 17) in 
order to prepare an active ester which can be easily derivatized with amino acids 
(Scheme 18) according to a procedure described in the literature37. 
 
 
Scheme 17: Synthesis of the NHS-ester of the linker acid 
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Scheme 18: Derivatization of the NHS ester of the 4-(allyloxy)-3,5-dichlorobenzoic acid with trans-2-
aminocyclohexanesulfonic acid and L-alanine 
The activated 4-(allyloxy)-3,5-dichlorobenzoic acid and L-alanine or the trans-2-
aminocyclohexanesulfonic acid reacted in aqueous acetonitrile in the presence of 
Hünig base to the corresponding amide. It has to be noted that the isolation of the 
products via extraction is not an easy task. Especially the aminosulfonic acid 
derivative was highly soluble in water and therefore we used continuous extraction 
for its isolation. This synthetic pathway was quite efficient and allowed us to prepare 
the strong cation exchanger type selector. The yield of the target compound using 
our synthetic procedure turned out to be higher than that of the published synthesis36. 
2.6.2 Derivatives of the 3,4,5-trimethoxybenzoic acid  
 
The derivatives of the 3,4,5-trimethoxybenzoic acid represent analytes for the 
evaluation of the mefloquine-based chiral stationary phases. The electron rich 
aromatic system of the acid should allow an effective  stacking with electron 
deficient quinoline core of mefloquine. 
An easy way for the synthesis of an amide is the Schotten-Baumann reaction 
between an acid chloride and an amino acid. This reaction is usually performed in a 
buffered mixture of polar organic solvent and water. We used commercially available 
3,4,5-trimethoxybenzoic acid chloride which reacted with leucine in 50% aqueous 
acetonitrile with sodium hydrogen carbonate as a base30 (Scheme 19). 
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Scheme 19: Amidation of 3,4,5-trimethoxybenzoic acid with L-leucine 
However, the Schotten-Baumann reaction did not turn out to be the right option for 
the synthesis of 17. One possible explanation is a bad quality of used chloride, which 
was stored in the laboratory for some time. Therefore we decided to completely 
hydrolyze this old material and transform the obtained acid into an active ester. For 
this purpose we again employed the Steglich esterification which proved to be 
efficient for the synthesis of the “linker acid” active ester. In this case 3,4,5-
trimethoxybenzoic acid reacted with N-hydroxysuccinimide in a DCC mediated, 
DMAP catalyzed esterification (Scheme 20). The corresponding active ester 18 was 
obtained in good yield. 
 
Scheme 20: Esterification of the 3,4,5-trimethoxybenzoic acid with N-hydroxysuccinimide  
The active ester 18 was further derivatized with L-alanine, L/D-alanine, L-leucine and 
D-leucine (Scheme 21). 
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Scheme 21: Syntheses of analytes based on 3,4,5-trimethoxybenzoic acid for the evaluation of the mefloquine based 
CSPs  
All analytes were prepared as enantiomerically pure compounds. 3,4,5-
trimethoxybenzoyl L- and D-leucine represent π-basic analytes which we designed as 
the first choice selectands for π-acidic mefloquine-based CSPs. Moreover, these SAs 
were further used for NMR study with tBuCMFQ, where we evaluated the chiral 
recognition properties of the novel selector. 
2.6.3 Derivatives of the pentafluorobenzoic acid 
 
The two trifluoromethyl groups of mefloquine open another option in a possible 
application of mefloquine-based selectors. We decided to design and synthesize 
analytes with a high mass percentage rate of fluorine to determine a possible effect 
of fluorophilic interactions between an analyte and the potential selector. We chose 
N-pentafluorobenzoyl (L)- and (D)-leucine as appropriate selectands.  
The Schotten-Baumann reaction with pentafluorobenzoic acid chloride and D-leucine 
turned out not to be the best choice again (Scheme 22). Simple monitoring of the 
reaction by TLC showed a slow progress but checking the product with HPLC 
revealed a mixture of compounds. It seems that under given conditions the chloride 
hydrolyzed faster than it reacted with the amino group of leucine. 
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Scheme 22: Schotten-Baumann reaction of the pentafluorobenzoic acid chloride with L-leucine 
The N-succinimidyl pentafluorobenzoic acid ester was synthesized in the same way 
as the other succinimide active esters (Scheme 23). 
 
Scheme 23: Synthesis of the NHS- ester based on pentafluorobenzoic acid 
The synthesis of target pentafluorobenzoyl L-and D-leucine proceeded in the same 
way as for the other analytes (Scheme 25). 
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Scheme 24: Amidation of the active ester of pentafluorobenzoic acid with D- or L-leucine (the stereocenter is not 
defined, but the synthesis was carried out with the enantiomerically pure amino acids) 
 
2.7 Synthesis of a strong cation exchanger based on O-allyl syringic acid 
 
The O-allyl syringic acid was chosen for the synthesis of a strong cation exchanger, a 
basic counterpart to the SCX CSP (16) based on the acidic linker acid 
developed in our working group37.  
 
Scheme 25: Synthesis of the O-allyl syringic acid 
At first, we used the standard allylation reaction with allyl bromide and potassium 
carbonate as a base in boiling acetone. This reaction was, however, too slow and 
thus after 2 days we added DMF in order to evaluate the influence of the better 
dipolar aprotic solvent. The reaction was finished in several hours and therefore the 
second reaction was carried out in DMF as a solvent (Scheme 25). The reaction 
mixture was heated up 60 °C in an oil bath and the reaction was accomplished in 
several hours. 
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Allyl 4-allyloxy-3,5-dimethoxybenzoate (24) could be easily transformed to the 
carboxylic acid 25 by hydrolysis. The basic reaction mixture was heated up, 
afterwards ice cooled and acidified. During this reaction only the ester function was 
affected not the alkoxy groups, which are stable under basic conditions. 
The active ester of O-allyl syringic acid was then the starting compound for the 
synthesis of the SCX. For its synthesis we decided to use the well-proven Steglich 
esterification with the O-allyl syringic acid, N-hydroxysuccinimide, the coupling 
reagent DCC and DMAP as a base (Scheme 26).  
 
Scheme 26: Steglich esterification of the O-allyl syringic acid 
We decided to perform the synthesis with racemic aminosulfonic acid (ACHSA) 
because the product can be easily enantioseparated. Therefore the activated 
carboxylic acid was derivatized with trans-2-aminocyclohexanesulfonic acid and the 
racemic strong cation exchanger was obtained (Scheme 27). 
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Scheme 27: Synthesis of a strong cation exchanger based on O-allyl syringic acid 
After the separation of enantiomers, which was performed on semipreparative 
column, the enantiomerically pure selector was immobilized on a 5 m 
mercaptopropyl modified silica gel. The immobilization was done in methanol, with 
AIBN and under nitrogen atmosphere. In comparison to previously prepared SCX, 
the coverage was slightly lower calculated by the nitrogen content (see experimental 
part). 
 
 
Scheme 28: Immobilization of the SCX CSP based on O-allyl syringic acid with AIBN 
However, the column shows great performances for the separation of basic amines 
and the mefloquine derivatives (see analytical part). 
 
In order to achieve a better coverage we changed the conditions for the 
immobilization. We employed a different radical starter which can be used in 
aqueous isopropanol. We supposed that the higher solubility of the selector in this 
solvent mixture would lead to a better reactivity and thus higher coverage. 
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Scheme 29: Immobilization of the SCX CSP based on O-allyl syringic acid with V-50 
 
Unfortunately a better coverage was not obtained.  
3. Analytical Part 
 
3.1 Determination of the elution order of N-allyl mefloquine 
 
For the separation of racemic N-allyl mefloquine diacetyl mono-tartrates were 
synthesized. Therefore we decided to functionalize quinine and quinidine, which are 
structurally related to mefloquine, with (R,R)-DATAAN as well. Although, QN/QD are 
usually called pseudoenantiomers they are in fact diastereoisomers. This can clearly 
be seen in Figure 14 where both QN and QD are separated on non-chiral stationary 
phase.  
The elution order of the quinine and quinidine derivatives could be compared with the 
elution order of the diacetyl monotartrates of MFQ. However, the reaction of QN and 
QD with (R,R)-DATAAN did not yield the expected product in a sufficient amount. 
This might have been caused either by lower activity of (R,R)-DATAAN, which is not 
very stable under long storage, or by hydrolysis of the product.  Finally, we 
accomplished the derivatization of QN/QD as well as mefloquine with (+)-(O,O)-
dibenzoyl-(R,R)-tartaric anhydride, which yielded more stable monoesters of 
respective compounds32.  
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Figure 14: Elution order of the (red) (8S,9R)-QN standard, the (green) (8R,9S)-QD standard, the (pink) (8S,9R)-QN-(O,O)-
dibenzoyl-(R,R)-tartaric acid monoester, the (military green) (8R,9S)-QD-(O,O)-dibenzoyl-(R,R)-tartaric acid monoester 
and the (blue) (O,O)-dibenzoyl-(R,R)-tartaric acid in RP mode. 
All measurements for the assignment of the elution order of N-allyl mefloquine were 
done on Eclipse C18 RP column (150 x 4,6mm; 5 µm) as stationary phase and as a 
mobile phase water with 2% AcOH/MeOH mixture was used. The following gradient 
was applied:  
Table 2: Gradient which was used for the assignment of the elution order of mefloquine32  
 
 
t [min] H2O+AcOH[%] MeOH[%]
0 50 50
5 35 65
10 20 80
15 20 80
20 35 65
25 50 50
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Figure 15: Elution order of N-allyl mefloquine. Colour code: (blue) (O,O)-dibenzoyl-(R,R)-tartaric acid, (red) (8S,9R)-QN-
DBTAM, (green) (8R,9S)-QD-DBTAM and (pink) N-allyl MFQ-DBTAM 
It was observed that the (O,O)-dibenzoyl-(R,R)-monotartrate of quinidine elutes 
before the quinine derivative and thus the elution order of the chinchona derivatives 
is (8R,9S) before (8S,9R). Because of the similarity of the chinchona derivatives to 
mefloquine we decided to assign the absolute configuration of the N-allyl mefloquine 
enantiomers in the same order32.  
For being absolutely sure of the absolute configuration we decided to carry out x-ray 
structure analysis of the assumed (9R,10S)-N-allyl mefloquine. The results of the x-
ray analysis confirm our assignment. 
 
Figure 16: X-ray structure of a co-crystal of (9R,10S)-N-allyl mefloquine and methyl-(O,O)-diacetyl-(R,R)-tartrate 
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3.2 Evaluation of the novel CSPs 
 
In this chapter the evaluation of different novel CSPs will be discussed. For 
describing the chromatographic behaviour we chose the following parameters, the 
retention factors ki, the selectivity factor αij, the theoretical plate number Ni and the 
chromatographic resolution R. 
The retention factor ki is defined as the quotient of the difference of the retention time 
of the compound ti and the void time t0. 
 
  
The retention factor indicates the interaction strength between a selector immobilized 
on the stationary phase and the analytes (selectand). The selector forms a kind of 
diastereomeric complex with each of the enantiomers and therefore the retention 
times differ. The retention time, and consequently the retention factor increases the 
stronger the interaction between the selector and the selectands gets. The retention 
factor is strongly dependent on the coverage of the selector on the stationary phase. 
Values between 1 and 5 are preferred for the retention factor, otherwise the retention 
time becomes too long or the interaction is too weak and no separation can be 
observed19,20. 
In following k1 and k2 are used for the retention factors of the first and the second 
eluting enantiomer. 
The selectivity factor αij is defined as the quotient of the retention factors. 
 
 
It represents the potential of a stationary phase to separate enantiomers. When the 
selectivity factor has a value of 1 no enantioseparation can be observed. That means 
that the selector of the chiral stationary phase does not prefer an interaction with one 
of the enantiomers. 
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The number of theoretical plates Ni is defined as follows: 
 
 
where b comprises the width of a peak at its base and bFWHM stands for the width of 
the peak at the half. 
The plate number N indicates the chromatographic performance or the efficiency of 
the column. The higher its value the sharper becomes the peak, and thus the 
efficiency of the column. One has to bear in mind that there are many parameters 
which influence the number of theoretical plates N, e.g. injection volume, composition 
of the mobile phase, coverage of the selector on the stationary phase, flow rate and 
so forth. Consequently, it is difficult to compare the number of plates with values 
reported in the literature. 
The chromatographic resolution R can be described with the Purnell equation: 
 
 
The resolution describes the distance between two peaks. According to the equation, 
the resolution depends on the interaction strength of analytes with the selector (the 
retention factor), on the enantioseparation capability of the chromatographic system 
(selectivity factor α) and on the peak shape (the plate number N). 
Another option for calculating the resolution is: 
 
 
where b is the width of the peak on the base and t the retention time. 
The presented R values as well as the N values in the following chapter (see below) 
were calculated automatically by the HPLC software, if not noted otherwise. 
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3.2.1 Evaluation of the mefloquine based CSPs 
 
The novel columns based on mefloquine selector, discussed in this section represent 
an anion exchanger type of CSP. Therefore, all the tested chiral analytes were of 
acidic nature. 
 
3.2.1.1 N-allyl mefloquine CSP and t-butylcarbamoyl-N-allyl mefloquine CSP 
 
The coverage of the selector immobilized on mercaptopropyl silica gel was in both 
cases low. In spite of that, the columns were laboratory-packed. The low coverage of 
the selector should only affect the retention times, not the capability for 
enantioseparation of the columns. In contrary to quinine, mefloquine is π-acidic and 
fluorophilic, therefore mainly π-basic analytes have been chosen for the evaluation of 
the columns.  
For the evaluation of the columns methanol with acetic acid and ammonium acetate 
in different concentrations was used as mobile phase. 
The chromatographic measurements were carried out on a 1100 series HPLC 
system from Agilent Technologies. The data analysis was done using the Agilent 
Technologies Chemstation software. Because all the analytes contained an aromatic 
moiety, 254 nm was chosen as the detection wavelength. The flow rate was set to 1 
mL/min and the void volume was determined by injection of acetone. The sample 
concentrations were 1 mg/mL methanol and the injection volume was 5 or 10 µL, 
depending on the UV response. 
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The following analytes were tested: 
 
 
Figure 17: Analytes for evaluation of the mefloquine based columns 
All analytes (except for DNB-Leu) were synthesized within the frame of this thesis 
(see Chapter 2). DNB-Leu analytes were previously prepared in our laboratory. For 
the derivatization of the 4-(allyloxy)-3,5-dichlorobenzoic acid (also called π-acidic 
linker acid) and the 4-O-allyl-syringic acid (also called π-basic syringic acid)  trans-2-
aminocyclohexanesulfonic acid was used. 
In general the retention factors were quite low and enantioseparation was only 
observed for the strongly acidic analytes based on trans-2-aminocyclohexanesulfonic 
acid. The retention factor could be slightly increased by decreasing the amount of 
acetic acid, actually the amount of ammonium acetate in the mobile phase, as it is 
shown in Figure 19. It seems that a carboxylic acid compared to the sulfonic acid, is 
too weak for a discrete ionic pair interaction with the tertiary amino group of the 
piperidine ring. 
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Figure 18: k1 values, mobile phase: MeOH, 0.5% AcOH, 0.125% NH4OAc 
 
 
Figure 19: Increase of the retention factor depending on the amount of ammonium acetate in the mobile phase 
(conditions see table 3). 
 
 
 
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
Re
te
nt
io
n f
ac
to
r k
1
Retention factor k1
(9R,10S)‐N‐
allyl‐MFQ
(9R,10S)‐N‐
allyl‐tBuCMFQ
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,5 0,25 0,125
Re
te
nt
io
n f
ac
to
r k
% of ammonium acetate
Retention factor
k1 of O‐ally‐trans‐syringic
ACHSA
k1 of O‐allyl‐trans‐linker
ACHSA
k2 O‐allyl‐trans‐syringic
ACHSA
k2 of O‐allyl‐trans‐linker
ACHSA
46 
 
Table 3: The α values of trans-2-aminocyclohexanesulfonic acid type analytes; mobile phase conditions: 1st row: 
MeOH, 1% AcOH, 0.25% NH4OAc; 2nd row: MeOH, 0.5% AcOH, 0.125% NH4OAc 
 
As a consequence of the low coverage of the selectors by immobilization and the 
obvious problems in enantioseparation we decided to carry out NMR studies. We 
assumed that such a study would clarify whether there is a complexation between 
the mefloquine-based selector and the selectands (see below). 
 
3.2.2 Evaluation of the SCX CSPs based on syringic acid 
 
As shown above, in spite of the low coverage of the mefloquine selectors, a 
separation of the enantiomers with the motif of aminosulfonic acid was observed. 
(see section 3.2.1.1). Therefore we decided to discover how the novel SCX CSPs 
based on syringic acid work for the enantioseparation of mefloquine based analytes.  
 
 
Figure 20: Novel SCX CSPs based on ACHSA and syringic acid. They represent enantiomeric CSPs to each other 
The coverage was calculated assuming that the novel SCXs is the ammonium salt of 
syringic acid derivative. However, it is possible that a mixture of the ammonium salt 
and the free selector is present. Therefore the coverage of carbons was determined 
in order to compare it with the calculated values for the nitrogen. The values are 
similar and therefore we can assume that the coverage corresponds to the presented 
values in Table 4 ((1R,2R)-CSP 3 and (1S,2S)-CSP 4). In general the coverage is 
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slightly lower for the novel SCXs than for the previously developed ones (CSP 3 vs. 
CSP 5 and CSP 4 vs. CSP 6). 
Table 4: Coverage of the novel SCX CSPs 
   µmol N/g µmol C/g
CSP3 153 164
CSP4 202 206
CSP5 184 ‐
CSP6 221 ‐
 
Figure 21 shows various analytes based on mefloquine, which were tested with and 
CSP 4. 
 
 
Figure 21: Analytes based on mefloquine for the evaluation of the novel SCX CSP. 
For estimation of the quality of the CSPs regarding selectivity and resolution, a 
comparison was done with a SCX CSP based on π-acidic linker acid ((1R,2R)-CSP5, 
see Figure 22). This SCX CSP was developed by a previous coworker and shows 
great applicability for the enantioseparation of basic analytes. 
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Figure 22: SCX CSPs which were previous developed in our working group  
As mobile phase a mixture of 90% ACN, 10% methanol with acidic and basic 
additives (50 mM formic acid and 25 mM DEA) as co- and counterion was used. The 
optimization of the mobile phase composition is an important parameter for 
optimising the elution strength. However, we used this composition of mobile phase, 
as it had already been optimized in our working group for the separation of chiral 
amines on CSP 5 and 6. The chromatographic measurements were carried out on a 
1100 Series HPLC or on a 1260 Infinity HPLC from Agilent Technologies. 
Chromatographic data analysis was done using the Agilent Chemstation software. 
For the presented chromatographic parameters in the following chapter 254 nm 
wavelength was chosen as detector signal. The flow rate was 1 mL/min and the 
injection volume was 5 or 10 µL. The concentration of the analytes was 1 mg/mL 
methanol. The void volume was determined by injection of 5 µL of methanolic 
acetone (70 µL/mL) solution. 
Table 5: Results for the evaluation of the novel SCX CSP 3 and 4 and for comparison CSP 5. 
 
Table 5 shows the chromatographic data of the separation of mefloquine based 
analytes. It can be seen that the novel SCXs based on O-allyl syringic acid are 
performing similarly to the established CSP 5. A comparison shows that the new 
columns provide better enantioseparation for all tested analytes. The CSP 5 is 
comparative to CSP 3 with regard to the configurations of the chiral centres. The 
elution order of N-allyl mefloquine was determined with the novel CSP 3 and 4. On 
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the CSP 3 the (9R,10S)-N-allyl mefloquine elutes before the (9S,10R)-N-allyl 
mefloquine and therefore on CSP 4 conversely. 
 
 
Figure 23: The retention factor k1 values for the SCX CSPs 
Figure 23 shows the retention factor k1 values for the SCX CSPs. CSP 5 shows a 
higher k1 value for mefloquine itself. The other values for the mefloquine-based 
analytes are similar for all CSPs. Furthermore, it has to be noted that the k1 values 
are higher, when the nitrogen of the piperidine ring in mefloquine is not derivatized. 
This fact indicates that the interaction strength of the selector with the selectand 
depends on the accessibility of the nitrogen in the piperidine ring. Moreover, 
additional H-bonding is possible in case of the free N-H (secondary amine) group. 
As the k1 values depend on the selector coverage on the silica surface, the direct 
comparison of the performance of columns is difficult.  
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Figure 24: α values for the SCX CSPs 
Figure 24 shows that the selectivity factor values for CSP 3 and 4 are slightly better 
or at least equal to CSP 5. CSP 3 and CSP 4 are enantiomerically to each other and 
this leads to a reversal of the elution order. The N-allyl tBuCMFQ was also tested on 
all columns; however, no enantioseparation was observed using the given mobile 
phase.  
By changing the mobile phase condition to methanol instead of acetonitrile the π-π 
interactions will be enhanced and the hydrogen bonding will be depressed. Thus, we 
changed the mobile phase and used MeOH with 50 mM formic acid and 25 mM 
diethyl amine for separation of N-allyl-tBuCMFQ on CSP 3 and 5. Enantioseparation 
was observed on CSP 3: α=1.06 or CSP 5: α=1.05 (same elution order). 
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Figure 25 shows that the resolution values are higher for CSP 3 than CSP 4 and 
CSP 5. Regarding CSPs 4 and 5 resolution is more or less equal for most of the 
analytes based on mefloquine. In general it can be seen that the resolution values for 
analytes where the nitrogen in the piperidine ring is substituted are lower. 
 
 
Figure 25: Resolution values for the SCX CSPs 
The structural resemblance of mefloquine with the chinchona derivatives was the 
motivation for analysing quinine, quinidine and the corresponding tert-butyl 
carbamates on CSP 3 and CSP 4. 
 
 
Figure 26: Analytes based on quinine and quinidine 
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Furthermore, for the evaluation of CSP 3 and CSP 4 several basic analytes were 
tested. Most of the tested analytes were secondary amines. The selected analytes 
are shown in Figure 27. 
 
 
Figure 27: Basic analytes for the evaluation of the novel SCX CSP 
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Table 6: Chromatographic data obtained by the evaluation of basic analytes with the novel SCX CSPs based on 
syringic acid. 
 
 
The elution order for some of the analytes like propranolol was determined, by 
injecting only one pure enantiomer of the analyte and comparing the retention time 
with the retention times of the racemic mixture. On CSP 4 the D enantiomers elute 
before the L enantiomers and therefore on CSP 3 conversely. 
  
Analyt k1 k2 alpha Res. N1[m-1] N2[m-1] k1 k2 alpha Res. N1[m-1] N2[m-1]
QN/QD 7,47 8,49 1,14 1,99 33087 32667 5,91 7,81 1,32 5,93 65240 62787
tBuCQN/tBuCQD 2,02 5,71 2,83 13,34 32007 33387 2,13 4,45 2,09 12,7 58920 59480
Propranolol 7,08 7,45 1,05 0,7 26420 27620 6,90 7,22 1,05 1,03 71907 72427
Norfenefrin HCl 3,97 5,27 1,33 1,17 2333 3153 - - - - - -
Isopenbutolol 5,51 6,12 1,11 1,64 34420 36107 4,99 5,45 1,09 1,93 70147 70373
Ephedrine HCl 6,86 7,78 1,13 2,17 38113 43873 5,09 5,73 1,13 2,74 78727 80740
Bamethan base 4,55 5,99 1,32 1,03 1713 2580 - - - - - -
Nifenalol 6,34 8,25 1,30 4,27 36187 37360 5,47 6,98 1,28 5,56 77373 75113
tBu-Propranolol 6,28 6,85 1,09 1,36 34887 35013 5,48 5,89 1,08 1,59 70507 70907
Sotalol*HCl 7,98 8,80 1,10 1,57 35227 35080 6,08 6,63 1,09 1,89 68627 69173
Metoprolol 4,95 5,11 1,03 0,49 25207 49573 4,35 4,49 1,03 0,61 51960 68527
Sotalol 7,94 8,72 1,10 1,22 18827 27647 6,08 6,62 1,09 1,88 68560 68713
8-Methoxy-tBu-propranolol 6,34 6,85 1,08 1,17 32047 32707 5,53 5,90 1,07 1,39 65973 67200
Dipivefrin*HCl 4,94 5,37 1,09 1,05 23707 26687 4,36 4,70 1,08 1,69 67653 72320
Formoterol 15,00 16,33 1,09 1,42 34547 34060 13,29 14,34 1,08 1,83 72327 70767
Butoxamine 4,28 5,21 1,22 2,96 36013 35387 3,76 4,63 1,23 4,17 67713 66587
Isoxsuprine HCl 6,63 8,08 1,22 3,09 31687 36233 5,03 6,08 1,21 3,99 67440 65307
Clenbuterol *HCl 7,32 9,53 1,30 4,34 36073 36760 6,23 7,94 1,27 5,5 71187 72907
Piperoxilidide 9,04 10,25 1,13 2,15 37873 38727 5,51 6,28 1,14 1,63 23873 22060
(1S,2S) CSP4 (1R,2R) CSP3
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Figure 28 shows the retention factor for the first eluting enantiomer. CSP 4 shows 
higher k1 values for all analytes. 
 
Figure 28: k1 values for basic analytes measured on syringic acid based SCX CSPs. 
Figure 29 shows slightly higher α values for analytes measured on CSP 4. 
 
 
Figure 29: α values for basic analytes measured on syringic acid based SCX CSPs. 
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Figure 30: Resolution values for basic analytes measured on syringic acid based SCX CSPs. 
Contrary to the k and the α values CSP 3 shows higher resolution values for the 
analytes than CSP 4. This is caused by the different number of plates in CSP 3 and 
4. As mentioned before the resolution values are, besides the α and the k values, 
influenced by the plates number. This indicates that the interaction strength of the 
(1S,2S)-CSP 4 with the selectands is higher than that of (1R,2R)-CSP 3. 
The number of plates also depends on the packing quality. The columns were 
packed in house and therefore a difference in the number of plates can be possible. 
Table 7: Shows selected analytes for comparison of CSP 4 (4-allyloxy-3,5-dimethoxybenzoyl derivative) and 6 (4-
allyloxy-3,5-dichlorobenzoyl derivative)  
 
The enantioseparation of CSP 3 is comparable to the established SCX CSP 6. 
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Analyt k1 k2 α Res. N1[m-1] N2[m-1] k1 k2 alpha Res. N1[m-1] N2[m-1]
QN/QD 9.45 10.91 1.15 2.96 55867 53867 7.47 8.49 1.14 1.99 33087 32667
tBuCQD/tBuCQN 2.82 9.34 3.31 19.3 49600 46067 2.02 5.71 2.83 13.34 32007 33387
Bamethan base 12.69 13.59 1.07 1.61 69000 68733 4.55 5.99 1.32 1.03 1713 2580
Nifenalol 8.15 11.05 1.36 6.69 63467 63733 6.34 8.25 1.30 4.27 36187 37360
Sotalol 8.40 9.49 1.13 2.66 62800 62867 7.94 8.72 1.10 1.22 18827 27647
Dipivefrin*HCl 6.15 6.85 1.11 2.23 59933 61867 4.94 5.37 1.09 1.05 23707 26687
Formoterol 18.19 20.54 1.13 2.71 59133 59333 15.00 16.33 1.09 1.42 34547 34060
tBu-Propranolol 7.66 8.49 1.11 2.22 63600 62733 6.28 6.85 1.09 1.36 34887 35013
Butoxamine 5.10 6.28 1.23 4.21 62200 61000 4.28 5.21 1.22 2.96 36013 35387
Isopenbutolol 7.02 7.75 1.10 2.09 61400 62000 5.51 6.12 1.11 1.64 34420 36107
Isoxsuprine 7.14 8.68 1.22 4.18 63267 61400 6.63 8.08 1.22 3.09 31687 36233
Clenbuterol *HCl 9.64 13.85 1.44 8.02 63533 62933 7.32 9.53 1.30 4.34 36073 36760
(1S,2S)-CSP6 (1S,2S)-CSP4
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Figure 31: Comparison of the α values for selected analytes on SCX CSPs 
The resolution is generally higher for the CSP 6 than for the CSP 4. 
 
Figure 32: Comparison of the resolution values of analytes measured on SCX CSPs 
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3.3 NMR studies of interactions between mefloquine and analytes 
 
The low selector coverage on silica used in the novel columns and the fact that 
enantioseparation can only be observed for sulfonic acid derivatives makes it difficult 
to decide, whether mefloquine fulfill the necessary interactions according to the three 
point model recomended for effective separation. Therefore we decided to carry out 
NMR studies as well.  
Recently, several detailed NMR studies concerning the specific interactions of 
cinchona derived chiral selector (SO) and negatively charged chiral selectands (SAs) 
have been published38,39. Following the chemical and functional reciprocity principle 
we envisioned that 9-O-tert-butylcarbamoyl-N-allyl mefloquine should follow similar 
intermolecular recognition pathways, as the 9-O-tert-butylcarbamoyl quinine type 
chiral SO but being driven by a -acidic quinoline moiety and a -basic counterpart of 
the selectand. 
We chose derivatives of 3,4,5-trimethoxybenzoic acid as appropriate selectands with 
sufficiently electron rich aromatic cores. Previously, the interactions of quinine-based 
selector with 3,5-dinitrobenzoylleucine were studied in our work group38. Therefore 
we decided to use leucine as a suitable amino acid part and synthesized N-3,4,5-
trimethoxybenzoyl leucine, which was used as a selectand during the initiate NMR 
study. Later on we decided to extend our study to 19F core measurements as well. 
We assumed that the trifluoromethyl groups of mefloquine may exhibit a kind of 
fluorophilic interactions with a fluoro substituted selectand. Such attractive forces 
may again enhance the chiral recognition and the selector itself might be helpful in 
trace analysis of herbicides and pesticides because many of them are nowadays 
fluorinated or perfluorinated. In order to discover whether such type of interactions is 
present, we prepared also N-2,3,4,5,6-pentafluorobenzoyl leucine. 
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Figure 33: a: Assignation of diagnostic protons of N-allyl-tBuCMFQ (other protons omitted for clarify); b: Assignation 
of diagnostic protons of L-Leu-TMB (other protons omitted for clarify) 
 
 
Figure 34: Atom numbering scheme of the N-allyl-tBuCMFQ and TMB-Leu 
 
Figure 35: Atom numbering scheme of the N-allyl-F-CMFQ and PFB--Leu 
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The NMR measurements were carried out in methanol-d4. This solvent was chosen 
for having comparable properties to an HPLC mobile phase. For the assignment of 
the interactions between the selector (mefloquine) and the selectand (TMB-DL-Leu, 
PBF-DL-Leu) a serial dilution was prepared40,41. A stock solution (20 µL/mL) was 
used for each of the compounds. Samples were prepared. A stock solution (20 
µL/mL) was used for each of the compounds. Samples were prepared, as shown in 
Table 8, by pipetting a given volume directly into an NMR tube. 
Table 8: Serial dilution of mefloquine based carbamates and the leucine derivatives 
(9S,10R)‐
tBuCMFQ 
DL‐Leu 
derivatives CMFQ
DL‐Leu 
derivatives 
[µmol]  [µmol] [µL] [µL] 
18 2 738 82 
16 4 656 164 
14 6 574 246 
12 8 492 328 
10 10 410 410 
8 12 328 492 
6 14 246 574 
4 16 164 656 
2 18 82 738 
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The first NMR study was carried out with (9S,10R)-N-allyl-tBuCMFQ and TMB-L-Leu, 
TMB-D-Leucine, respectively. The corresponding job plot of 1H NMR is shown in 
Figure 36 for the H-9 (a diagnostic proton located at C-9 chiral centre). 
 
Figure 36: Job plot for the diastereomeric complexes of (9S,10R)-N-allyl-tBuCMFQ and TMB-D-Leu, TMB-L-Leu 
respectively. The chiral H-9 of mefloquine was used for interpretation. The total concentration was 20 µM. 
Figure 36 shows that a stoichiometric 1:1 complex of the mefloquine based selector 
and the leucine derivatives is formed. It has to be noted that the complexation of 
TMB-L-Leu is weaker than that of TMB-D-Leu. 
The presence of two trifluoromethyl groups in the mefloquine molecule makes it 
interesting also for 19F NMR studies with the advantage that 19F NMR spectra are 
usually much easier to interpret because of a reduced number of fluorinated 
functionalities signals. In Figure 37 and Figure 38 the corresponding 19F NMR job 
plot is shown for the trifluoromethyl groups of mefloquine. 
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Figure 37: Job plot for the diastereomeric complexes of (9S,10R)-N-allyl-tBuCMFQ and TMB-D-Leu, TMB-L-Leu 
respectively. The CF3 (C-17) group was used for interpretation (62.0 ppm). The total concentration was 20 µM. 
It can be observed that the complexation of TMB-L-Leu and mefloquine carbamate 
increase with the amount of the selector constantly. Contrary to this the interaction 
strength between TMB-D-Leu and mefloquine carbamate increases slightly until a 
ratio of 1:1 SO:SA, where it collapsed and afterwards it increase again. 
 
Figure 38: Job plot for the diastereomeric complexes of (9S,10R)-N-allyl-tBuCMFQ and TMB-D-Leu TMB-L-Leu 
respectively. The CF3 (C-16) group was used for interpretation (69.9 ppm). The total concentration was 20 µM. 
Figure 38 shows that the interaction strength of TMB-D-Leu with (9S,10R)-N-allyl-
tBuCMFQ is higher than the one of TMB-L-Leu. In general the same parabolic trend 
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of complexation can be observed for the selectands and the mefloquine carbamate 
with the highest point for 0.4 molar fraction of the selector. 
These results indicate that the complexation of mefloquine with TMB-Leu is probably 
not based on strong  interactions and thus the CF3 (C-17) group is almost not 
affected. Therefore we decided to carry out a job plot for (9S,10R)-N-allyl-tBuCMFQ 
and PFB-D-Leu. We expected that we could observe stronger interactions between 
SO and SA based on fluorophilic interactions between the perflourinated core of 
protecting group and triflouromethyl groups of mefloquine. Because of stronger 
complex SO-D-Leu (see above) we decided to carry out the job plot measurement 
only with PFB-D-Leu. 
 
 
Figure 39: Job plot for the diastereomeric complexes of (9S,10R)-N-allyl-tBuCMFQ and PFB-D-Leu. The chiral H-9 of 
mefloquine was used for interpretation. The total concentration was 20 µM. 
Figure 39 shows a similar parabolic behaviour for the chiral proton located at the 
stereogenic centre of mefloquine like the complexation of the mefloquine carbamate 
and the TMB-D-Leu. However, in this case the highest interaction strength is 
observed by a molar ratio 0.4 of (9S,10R)-N-allyl-tBuCMFQ and 0.6 of PFB-D-Leu. 
Also it has to be noted that the SO-SA interaction is in this case almost 10 times 
weaker than for non-fluorinated SA (TMB-D-Leu). 
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Figure 40: Job plot for the complexation of (9S,10R)-N-allyl-tBuCMFQ and  PFB-D-Leu. The chiral H-102 of the 
fluorinated D-leucine derivative was used for interpretation. The total concentration was 20 µM. 
For the chiral proton located on the stereogenic centre of the PFB-D-Leu it can be 
seen (Figure 40) that the interaction strength decreases with the amount of 
selectand. This could be caused by increasing dimerization of the selectand with its 
increasing concentration42.That would mean that the fluorophilic interactions take 
place rather between two molecules of the SA than between one molecule of SO and 
one molecule of SA. Such behaviour would be further favoured by strong tendency of 
carboxylic acids to dimerize43. 
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Figure 41: Job plot for the diastereomeric complexes of (9S,10R)-N-allyl-tBuCMFQ and PFB-D-Leu. The CF3 groups of 
mefloquine were used for interpretation. The total concentration was 20 µM. 
For the trifluoromethyl groups of mefloquine no defined interactions can be observed, 
as it is seen in Figure 41. 
In comparison to N-allyl-tBuCMFQ-TMB-Leu couple the CISs of trifluoromethyl 
groups are again almost 10 times weaker. In such a case it is hard to say whether 
the observed shifts are caused by direct SO-SA interaction or by some kind of 
diffusion processes in the diluted solution. 
 
Figure 42: Job plot for the diastereomeric complexes of (9S,10R)-N-allyl-tBuCMFQ and PFB-D-Leu. The F signals of 
PFB-D-Leu were used for interpretation. The total concentration was 20 µM. 
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For the fluorine signals of the benzoyl group of the selectand also no defined 
interaction can be observed, with the exception of the fluorine atom in the para 
position. It exhibits a parabolic interaction profile (see Figure 42) with the highest 
interaction strength at 30% of the PFB-D-Leu. This behaviour might be caused by 
concentration dependent dimerization of the acid. That would mean that the 
interaction with the selector increased until a molar ration of 0.3 and 0.7 of SA and 
SO, respectively. After reaching this limit concentration the dimerization prevailed 
and the hydrogen bonding between piperidine nitrogen of the SO and the carboxylic 
group of the SA diminished. 
Such behaviour would also explain the shift of para-fluorine of the SA, which is 
according to Hammett equation the most influenced functional group by hydrogen 
bonding of the carboxylic group44. 
Because we were not able to induce fluorophilic interaction by changing the structure 
of the protective group of the SA, we decided to modify also the structure of the 
mefloquine SO. We synthesized 3,5-bis{trifluoromethyl}phenylcarbamoyl-N-allyl 
mefloquine and carried out an NMR study with the pentafluorobenzoyl L-leucine 
(PFB-L-Leu) and pentafluorobenzoyl D-leucine (PFB-D-Leu). This selector and 
selectand should have stronger π-π- and fluorophilic interactions than the non-
fluorinated ones. 
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Figure 43: Job plot for the diastereomeric complexes of (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, PFB-L-Leu respectively. The diagnostic H-9 of mefloquine was used for interpretation. The 
total concentration was 20 µM. 
Figure 43 shows that there is no interaction between the selector and the selectand, 
the pentafluorobenzoyl L-Leu anymore. For pentafluorobenzoyl D-Leu it seems that 
interactions between the selector and the selectand occure only at higher 
concentrations of the selector and at lower concentrations, than a stoichiometric 1:1 
ratio, no interactions can be observed. 
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Figure 44: Job plot for the diastereomeric complexes of (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, PFB-L-Leu respectively. The chiral H-102 of the fluorinated leucine derivatives was used 
for interpretation. The total concentration was 20 µM (the point at 0.3 molar fraction is a discordant value). 
Figure 44 shows that no interaction can be observed for PFB-L-Leu with the 
fluorinated mefloquine selector. TMB-D-Leu exhibited the increasing interactions 
depending on the amount of selectand and they drop significantly once a 
complexation ratio of 1:1 was achieved. 
Here we can again speculate about some kind of concentration dependent 
dimerization, which is supported by the linearity of the interactions depicted in Figure 
43 and Figure 44. However, in this case the dimer formation would be higher for 
lower concentrations of the acid, which is in contradiction to the theory and observed 
behaviour39,42. In order to clarify our observations additional experiments with a 
higher concentration of SO and SA are needed. 
We also performed 19F NMR measurements in the hope that we will obtain some 
additional information from potential fluorophilic interactions. 
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Figure 45: Job plot for the diastereomeric complexes of (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, PFB-L-Leu respectively. The CF3 (C-17) group of fluorinated mefloquine carbamate was 
used for interpretation (62.0 ppm). The total concentration was 20 µM. 
Figure 45 and 46 show that almost no interaction can be observed among the 
trifluoromethyl groups of the quinoline ring (62.0 ppm) and the one of the carbamate 
functionality (65.1 ppm) and the pentafluorobenzoyl moiety of PFB-L-Leu. The CIS of 
the CF3 groups increased only slightly with increasing concentration of the selector.  
 
 
Figure 46: Job plot for the diastereomeric complexes of the (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, OFB-L-Leu respectively. The CF3 group of the fluorinated carbamate functionality of 
mefloquine was used for interpretation (65.1 ppm). The total concentration was 20 µM. 
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Figure 47 shows slightly increasing interactions of PFB-D-Leu with the amount of 
fluorinated carbamate interpreted for the trifluoromethyl group next to the nitrogen in 
the quinoline of mefloquine (69.9ppm). For PFB-L-Leu the interactions increase with 
the amount of the selector. 
 
 
Figure 47: Job plot for the diastereomeric complexes of (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, PFB-L-Leu respectively. The CF3 group (C-16) of fluorinated mefloquine carbamate was 
used for interpretation (69.9 ppm). The total concentration was 20 µM. 
0,0000
0,0001
0,0002
0,0003
0,0004
0,0005
0,0006
0,0007
0,0008
0,0009
0 0,2 0,4 0,6 0,8 1x
 ((9
R,
10
S)
‐N‐
al
ly
l‐F
‐CM
FQ
)*
Δδ
(p
pm
)
x ((9R,10S)‐N‐allyl‐F‐CMFQ)
CF3 group(69.9ppm)
PFB‐L‐Leu
PFB‐D‐Leu
70 
 
 
Figure 48: Job plot for the diastereomeric complexes of (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, PFB-L-Leu respectively. The ortho F of fluorinated leucine deivative was used for 
interpretation. The total concentration was 20 µM. 
 
For the F- signals of the selectand (pentafluorobenzoyl-leucine) the same trend can 
be observed (seen in Figure 48, 49, 50). For PFB-L-Leu the interactions increase 
until 0.3 molar fraction of selectand and then an increase of interactions can be 
observed. For PFB-D-Leu almost no interactions of the selectand and the selector 
can be observed. 
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Figure 49: Job plot for the diastereomeric complexes of (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, PFB-L-Leu respectively. The para F of fluorinated leucine deivative was used for 
interpretation. The total concentration was 20 µM. 
 
Figure 50: Job plot for the diastereomeric complexes of (9R,10S)-N-allyl-3,5-bis{trifluoromethyl}phenylcarbamoyl 
mefloquine and PFB-D-Leu, PFB-L-Leu respectively. The meta F of fluorinated leucine deivative was used for 
interpretation. The total concentration was 20 µM. 
 
The expected increase of fluorophilic interactions by using the polyfluorinated 
mefloquine selector with the polyfluorinated selectand was not observed. Despite the 
high amount of fluorine in the selector and the selectand it seems that the 
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electrostatic interactions (like hydrogen bonding, formation of ion pairs) and the steric 
interactions are the main interactions for the enantiodiscrimination. 
In general, interactions of the mefloquine carbamates and the selectands seemed to 
be much weaker compared to previous job plots which were carried out for 
chinchona derivatives and DNB-Leu38. Therefore we decided to carry out a job plot 
with (9S,8R)-tBuCQD and PFB-D-Leu. We chose quinidine carbamate because of 
the similarity to the mefloquine carbamate in terms of absolute configuration at C-9 
and C-10 which allow us a direct comparison with the mefloquine selector. 
 
Figure 51: Job plot for the complexes of (9S,8R)-tBuCQD and PFB-D-Leu. The chiral H-9 of quinidine was used for 
interpretation. The total concentration was 20 µM. 
Figure 51 shows a parabolic interaction profile of the quinidine carbamate and the 
PFB-D-Leu, similar to the one of the (9S,10R)-N-allyl-tBuCMFQ and the PFB-D-Leu 
with the exception that the highest interaction strength was observed for 0.3 mol 
fraction of quinidine carbamate. However, the interaction strength is about 10 times 
higher in case of tBuCQD than that of tBuCMFQ. 
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Figure 52: Job plot for the complexes of (9S,8R)-tBuCQD and PFB-D-Leu. The chiral H-102 of the fluorinated D-leucine 
derivative was used for interpretation. The total concentration was 20 µM. 
The interaction strength of the PFB-D-Leu and the (9S,8R)-tBuCQD decreased with 
increasing concentration of PFB-D-Leu interpreted for the chiral proton located at the 
stereogenic centre of the selectand (see Figure 52). This might again be caused by 
dimerization of PFB-D-Leu as a similar behaviour was observed for the mefloquine 
carabamate and the same selectand.  
 
Figure 53: Job plot for the diastereomeric complexes of (9S,8R)-tBuCQD and PFB-D-Leu. The F signals 
 of PFB-D-Leu were used for interpretation. The total concentration was 20 µM. 
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The interactions of (9S,8R)-tBuCQD and PFB-D-Leu according to the fluorine signals 
of the selectand seem more directed than for (9S,10R)-N-allyl-tBuCMFQ and PFB-D-
Leu. On the basis that quinidine has no fluorines the interactions cannot be driven by 
fluorophilic interactions. The electrostatic and steric interactions are most probably 
responsible for the enantiodiscrimination. The highest interaction strength is 
observed for ortho-fluorine and the lowest for meta-fluorine. As shown in Figure 53 
the interaction strength profile is again parabolic, with the maximum at 1:1 ratio of 
selector and selectand (meta-fluorine) or at 0.6 molar fraction of the selectand for 
para-fluorine. This corresponds with the shift of electron density in the aromatic core 
caused by hydrogen bonding44. As the CISs were generally more pronounced in this 
case, we assume that also an effective although weak π-π stacking was involved. 
 
4. Discussion and Conclusion 
4.1 Novel chiral stationary phases for HPLC 
 
Chiral stationary phases based on N-allyl mefloquine 
The evaluation of the N-allyl mefloquine based CSPs showed that enantioseparation 
could only be observed for analytes based on sulfonic acids. In general retention 
factors were quite low because of the low coverage of the selector on CSPs which 
was a consequence of immobilization problems. Despite optimization trials, no 
coverage improvement was observed; however, there are still options which can be 
tried to achieve better coverage in the future. Furthermore, the evaluation of the 
mefloquine based CSPs was done with a relatively small analyte set which should be 
expanded for a full characterization of the applicabilities of the novel CSPs. Therefore 
at least mobile phase composition should be varied. 
Nevertheless, once the coverage of the selector is improved, mefloquine based 
CSPs should become an effective tool for separation of at least derivatives of sulfonic 
acids. 
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Novel SCX CSPs based on syringic acid 
The novel SCX CSPs were developed for the analysis of mefloquine-based analytes. 
The evaluation showed that the new columns provide enantioseparation for all these 
compounds, except for N-allyl-tBuCMFQ. By enhancing π-π interactions with varying 
the composition of the mobile phase, we were able to achieve enantioseparation for 
N-allyl-tBuCMFQ. In general, the applicability of the new CSPs has to be further 
tested under different mobile phase conditions.  
Moreover, we observed that the enantioseparation was improved for mefloquine 
derivatives where the nitrogen in the piperidine moiety remains non-derivatized and 
remains a secondary amino group. As a consequence of this fact, we designed a 
novel selector based on mefloquine which has a free nitrogen in the piperidine ring. 
This compound will be synthesized in frame of a subsequent diploma thesis.  
The novel SCX CSPs showed also enantioseparation for several basic analytes. The 
(1S,2S) CSP 4 shows slightly higher retention factors and selectivity values. On the 
other hand, (1R,2R) CSP 3 shows higher resolution values than CSP 4. This 
difference was caused by higher number of plates in case of CSP 3, which can be 
explained by an inhomogeneous packing of the column. Because CSP 3 and 4 are 
enantiomeric to each other, they also allowed the determination of elution orders of 
the analytes. 
 
4.2 NMR studies of interactions between mefloquine and analytes 
 
1H-NMR and 19F-NMR studies were carried out for the determination of complexation 
strength between mefloquine-based selectors and leucine derivatives.  
 
NMR study for complexation of (9S,10R)-N-allyl-tBuCMFQ and TMB-DL-Leu 
 
The interpretation of the 1H-NMR job plot of the diagnostic proton located at the 
stereogenic centre C-9 shows (Figure 36) the strongest interaction strength at the  
equivalent amount of the selector and the selectand, which indicates that a 1:1 
complex is formed. Based on the CISs obtained by NMR we assigned the complex 
with TMB-D-Leu as the stonger one. That means that in case of an efficient HPLC 
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column the TMB-D-Leu would be the more retained enantiomer. This result is 
completely in accordance with the well-established Chiralpak QD-AX column where 
(R)-enantiomers usually elutes before (S)-enantiomers.  
The 19F-NMR job plot of the trifluoromethyl groups shows different interaction 
behaviour (see Figure 37 and 38) compared to the 1H-NMR job plot of the proton 
located at C-9. The complexation behaviour of the trifluoromethyl group located next 
to the nitrogen in the quinoline (69.9ppm) is parabolic with the highest shift by a ratio 
of 3:2 SA:SO. This indicates directed interactions of the selector and the selectand, 
at least in terms of protonation of nitrogen of the piperidine ring. 
The second trifluoromethyl group shows an exponential behaviour for the interaction 
of TMB-L-Leu with increasing concentration of mefloquine carbamate, whereas TMB-
D-Leu shows an exponential behaviour until an equivalent amount of selector and 
selectand is achieved.  
In general, the chemical shift in NMR depends on the concentration of analytes. As a 
result, by constantly varying the concentration of the analyte the chemical shifts will 
change directly as well. If there are no specific interactions between the selector and 
the selectand, the difference in chemical shifts will be only concentration dependent. 
It is hard to say, if the exponential behaviour interpreted for trifluoromethyl group 
(62.0ppm) occurred only because of variation of the concentration or by other 
reasons, like unspecific interactions. Because the interaction strength is generally 
quite low, we suppose that this behaviour can be explained by insufficient SO-SA π-π 
stacking. As it is shown in Figure 33 the aromatic part of TMB-Leu is quite spatially 
demanding, which most probably led to disruption of the π-π stacking. In that case the 
CISs, we observed, were only concentration dependent. 
 
NMR study for complexation of (9S,10R)-N-allyl-tBuMFQ and PFB-D-Leu 
 
In the hope to induce additional directed fluorophilic interactions between the selector 
and the selectand, we decided to carry out a job plot for (9S,10R)-N-allyl-tBuCMFQ 
and PFB-D-Leu.  
For the diagnostic proton located at the sterogenic centre C-9 a parabolic interaction 
behaviour calculated for shift differences was observed. The maximum was observed 
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at a ratio of 7:3 SA:SO. Nevertheless a higher interaction strength caused by 
additional flourophilic interactions was not observed compared to the job plot where 
TMB-D-Leu was used as the selectand. The parabolic complexation behaviour 
indicates that directed interaction took place between the selector and the selectand. 
The diagnostic proton located at the stereogenic centre of the PFB-D-Leu exhibited 
an exponential decrease with increasing concentration of the selectand. This 
indicates that interactions between selector and selectand are located in the region of 
the stereogenic centre of mefloquine carbamate and do not influence the stereogenic 
centre of the selectand. Such behaviour indicates that PFB-D-Leu favours 
dimerization at higher concentration. This can be ascribed to the ability of carboxylic 
acids to dimerize which in this case is supported by fluorophilic interactions between 
the pentafluorobenzoyl moieties.  
Interpretation of the CISs of the trifluoromethyl groups of (9S,10R)-N-allyl-tBuCMFQ 
and the fluorine atoms of PFB-D-Leu  measured with 19F-NMR indicates only a 
specific interaction like ion pairing which influenced only para-fluorine in PFB-D-Leu.  
In general no fluorophilic interactions were observed, because such interactions 
would influence the complexation behaviour of the 19F signals in a similar way and 
there is no trend which can be observed. Consequently we decided to enhance the 
amount of fluorine with an expectation, if fluorophilic interactions are achievable they 
have to be observable with a high amount of fluorine. 
 
NMR study for complexation of (9R,10S)-N-allyl-F-MFQ and PFB-DL-Leu 
 
As mentioned before we decided to carry out 1H-NMR and 19F-NMR studies with 
(9R,10S)-N-allyl-3,5-bis-{trifluoromethyl}phenylcarbamoyl mefloquine, and PFB-L-
Leu and PFB-D-Leu, in order to improve fluorophilic interactions. We also supposed 
that the additional aromatic functionality of the mefloquine carbamate could enhance 
π-π interactions abilities of the selector. 
As a consequence of the reversal of absolute configuration of the (9R,10S)-N-allyl-F-
CMFQ compared to the previous NMR studies (9S,10R)-N-allyl-tBuCMFQ, we 
suggested that the CISs are higher for PFB-L-Leu than for PFB-D-Leu. However, no 
defined complexation behaviour between the selector and the selectands can be 
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observed for the stereogenic protons of selector and selectand measured with 1H-
NMR.  
Generally it seems that the high amount of fluorine (in total 17 fluorine) in the selector 
and the selectand disturb selective interactions. The CISs of trifluoromethyl groups 
and fluorine atoms of the selectand indicate that formation of dimers is probably a 
preferred form of interaction. This theory has to be confirmed by NMR experiments at 
higher concentrations. 
 
NMR study for complexation of (9S,8R)-tBuCQD and PFB-D-Leu 
 
For a direct comparison of the behaviour of our new selector we decided to carry out 
a 1H-NMR and a 19F-NMR study with tBuCQD and PFB-D-Leu.  
Interpretation of the complexation induced shifts for the proton located at the 
stereogenic centre C-9 of quinidine showed a parabolic behaviour with the maximum 
at 0.3 molar fraction of tBuCQD, which is comparable to the mefloquine selector. 
For the proton located at the stereogenic centre of PFB-D-Leu an almost linear 
decrease can be observed, perhaps caused by the variation of the concentration or 
by formation of dimers caused by favoured PFB-Leu:PFB-Leu interactions.  
The interpretation of the 19F-NMR study shows that the interaction of the quinidine 
carbamate and the PFB-D-Leu generated a parabolic profile for the fluorine signals 
as well. These interactions are most probably of electrostatic nature. Compared to 
the NMR study carried out with mefloquine carbamate, where only the para 
substituted fluorine shows a similar behaviour, it seems that in case of quinidine also 
π - π stacking took place. 
 
Conclusion: 
 
NMR studies are a convenient method to determine the applicability of a novel 
selector for enantioseparation. Therefore only 150 mg of the novel selector is needed 
and so it is not necessary to synthesize the novel selector in a big scale, which is 
often quite time-consuming and expensive.  
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Based on the results of the NMR study, we can say that the N-allyl-tBuCMFQ 
selector is not as efficient for enantioseparation as the tBuCQD selector.  
 
5. Materials and Instruments 
 
Mefloquine hydrochloride was purchased from Kreamer & Martin Pharma Handels-
GmbH (Germany). Synthesis reagents were predominantly purchased by Sigma 
Aldrich (Vienna, Austria) and were of reagent grade or higher purity. The solvents 
used for syntheses were of technical grade and purchased from VWR (Darmstadt, 
Germany). The HPLC grade solvents were acquired from VWR (Darmstadt, 
Germany), from Sigma-Aldrich (Vienna,Austria) or from Carl Roth GesmBH 
(Karlsruhe, Germany). 
Mobile phase additives (diethylamine, formic acid, etc.) were either from Sigma-
Aldrich or Fluka (via Sigma Aldrich, Germany). 
The NMR solvents were purchased from Deutero GesmBH (Kastellaun, Germany). 
Analytes for evaluation of novel SCX and AX columns were synthesized on our own, 
by coworkers or were gifts from other research groups. 
Reactions were often controlled with TLC plates on Silica gel 60 F254 (Merck, 
Germany) with UV detection at 254 nm in a cabinet from CAMAG. The silica gel 60 
which was used for column chromatography in order to purify syntheses products 
was purchased from Merck KGAA (Darmstadt, Germany) 
MS measurements were performed on 4000 Q TRAP LC/MS/MS System (AB 
Applied MDS SCIEX) with a ESI source for ionisation and the coupled HPLC system 
was from Agilent Technologies (Series 1200). 
NMR measurements were carried out on a Bruker DRX 600 MHz or DRX 400 MHz 
NMR spectrometer. NMR spectra were evaluated with the NMR software SpinWorks. 
Elemental analysis from the immobilized selectors on mercaptopropyl was performed 
on EA 3000 (eurovector). 
Melting points were performed on a Kofler from GallenTM III Reichert Jung. 
HPLC measurements were carried out either on a 1100 Series HPLC or on a 1260 
Infinity HPLC from Agilent Technologies. 
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6. Experimental 
 
6.1 Synthesis of the starting material N-allyl mefloquine  
 
N-allyl mefloquine (2): 
In a 250 mL round bottom flask the MFQ salt (1) (10.0 g; 24 mmol) and K2CO3 (3.33 
g; 24 mmol) were placed with a stirrer. The flask was flushed with nitrogen. Dry DMF 
(60 mL) was added and the suspension was stirred for 15 min.  Subsequently, allyl 
bromide (2.09 mL; 24 mmol) was added, the nitrogen source was removed and the 
reaction flask was fitted with a drying tube (CaCl2). The reaction mixture was stirred 
for 17 h at room temperature, diluted with distilled water (150 mL) and stirred further 
for 30 min. The precipitate was filtered, washed with methanol (2x20 mL) and dried in 
vacuum. The crude product was purified by crystallization from methanol6. It was 
obtained 6.94 g (69%) of compound 2; m.p 124.8-125.9 °C; m.p. lit.6 121-123 °C. 
1H NMR (400 MHz,CDCl3): 0.74(m); 0.94(d); 1.08(m); 1.33(m); 1.576(m); 1.72(m); 
1.92(m); 2.05(m); 2.22(m); 2.80(s); 2.88(s); 2.93(m); 3.24(m); 3.41(d); 3.63(d); 
3.74(m); 3.98(d); 4.07(dd); 4.17(m); 4.69(m); 4.87(d); 5.13(d); 5.26(dd); 5.35(d); 
5.42(s); 5.47(s); 5.74(d) ;5.91(m); 5.96(s); 6.08(m); 6.22(m); 6.28(s); 6.45(s); 7.15(t); 
7.62(t); 7.73(m); 7.93(m); 8.01(s); 8.05(t); 8.15(d); 8.94(d).  
The complexity of the spectrum did not allow a precise assignment of all signals. 
 
N-allyl-mefloquine HCl salt (2c): 
To a solution of 2 (0.20 g; 0.48 mmol) in methanol (10 mL), a 3 M solution of HCl in 
methanol (239 µL; 0.71 mmol) was added. The reaction mixture was stirred without 
presence of air moisture (CaCl2 drying tube) at room temperature over night. 
Evaporation of the solvent afforded 0.19 g (87%) of 2c. 1H NMR (400 MHz, MeOD): 
1.0 (d, 1 H, CH2); 1.3 (dt, 2 H, CH2); 1.75 (m, 2 H, CH2); 1.85 (m, 2 H, CH2); 3.2 (dt, 2 
H, CH2); 3.6 (d, 1 H, CH); 3.8 (d,1 H, CH); 4.2 (dt, 1 H, CH); 4.4 (dd, 1 H, CH); 5.85 
(m, 2 H, CH2); 6.3 (m ,2 H, CH2); 8.0 (t, 1 H, J = 8.0 Hz, CH); 8.2 (s,1 H, CH); 8.3 (d, 
1 H, J = 7.3 Hz, CH); 8.4 (d, 1 H, J = 8.5 Hz, CH). 13C NMR (100 MHz, MeOD): 
23.0(CH2); 24.5(CH2); 25.0(CH2); 54.7(CH2); 57.0(CH2); 66.4(CH); 66.7(CH); 
117.4(CH); 124.0(Car); 126.8(CF3); 127.3(CH2=CH); 127.8(CF3); 128.4(CHar); 
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129.2(CHar); 129.9(CHar); 131.0(CH=CH2); 145.3(Car); 149.5(Car); 149.9 (Car); 
151.6(Car). 
 
(9S,10R)-N-allyl mefloquine (O,O)-diacetyl-(R,R) mono-tartrate (3a): 
In a 250 mL nitrogen flushed round bottom flask N-allyl mefloquine (2) (6 g; 14.34 
mmol) and (R,R)-DATAAN (7.75 g; 35.85 mmol) were placed with a stirrer. Dry DCM 
(60 mL) was added and the solution was stirred over night. To avoid decomposition 
of the anhydride because of humidity the flask was fitted with a drying tube (CaCl2). 
The reaction mixture was extracted with 5% aqueous NaHCO3 (150 mL; pH~ 8 of the 
water layer), with 10% aqueous HCOOH (100 mL) and with saturated solution of 
NaCl (20 mL). The organic layer was dried with MgSO4 and the solvent was 
evaporated. The crude racemic product (8.5 g; 93%) was placed in a soxhlet 
extractor and continuously washed with toluene for 6 h. The crystals (97% de) were 
removed from the extraction tube, dissolved in a solution of tert-butyl methyl ether 
and ACN, and the solvent was evaporated. The resulting solid was placed into the 
soxhlet extractor and washed with hot toluene further for 6 h. The system was left to 
cool down to room temperature and the monotartrate 3a 3.6 g (93 %) was obtained 
as a crystalline material from the soxhlet extractor tube. m.p.186.2-187.8 °C. 
1H NMR (400 MHz, CDCl3): 1.21 (m, 1 H, CH2); 1.35 (m, 1 H, CH2); 1.91 (m, 2 H, 
CH2); 2.05 (s, 3 H, CH3C=O); 2.07 (s, 3 H, CH3C=O); 2.25 (m, 1 H, CH2); 2.48 (m, 1 
H, CH2); 3.07 (m, 1 H, CH2); 2.42 (m, 1 H, CH2); 3.75 (m, 1 H, CH2); 4.21 (m, 1 H, 
CH2); 4.49 (m, 1 H, CH); 5.71 (s, 1 H, CH); 5.83 (d, 1 H, CH2=); 5.88 (d, 1 H, CH2=); 
6.30 (m, 1 H, CH=); 6.57 (bs, 2 H, 2xCH); 7.80 (t, 1 H, J = 7.6 Hz, CH); 7.98 (s, 1 H, 
CH); 8.03 (d, 1 H, J = 8.3 Hz, CH);  8.16 (d, 1 H, J = 7.4 Hz, CH). 13C NMR (100 
MHz, CDCl3): 20.0(CH3); 20.7(CH3); 22.8(CH2); 24.1(CH2); 24.3(CH2); 56.2(CH2); 
58.5(CH2); 66.7(CH); 70.1(CH); 74.4(CH); 74.8(CH); 117.3(CHar); 123.6(Car); 
126.8(Car); 128.1(CH2=); 128.8(CF3); 129.0(CHar); 129.7(CH=); 129.9(CF3); 
130.8(CHar); 130.9(CHar); 145.0(Car); 145.2(Car); 148.7(Car); 168.0 (C=O); 
171.9(C=O); 172.0(C=O); 172.8 (C=O).  
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(9R,10S)-N-allyl mefloquine (O,O)-diacetyl-(R,R)-mono-tartrate (3b): 
The extraction solvent was evaporated and the crude product was crystallized from 
MeOH. It was obtained 3.0 g (77%) of the diastereomer 3b, m.p.: (9R) 195.4-196.9 
°C. The reaction control was performed with HPLC (mobile phase: 50% H2O and 
0.1% FA; 50% ACN and 0.1 % FA; stationary phase: eclipse XDB-C18 5 µm, 4.6 x 
150 mm). 
1H NMR (400 MHz, CDCl3): 1.18 (m, 1 H, CH2); 1.28 (m, 1 H, CH2); 1.85 (m, 2 H, 
CH2); 2.05 (s, 3 H, CH3C=O); 2.07 (s, 3 H, CH3C=O); 2.22 (m, 1 H, CH2); 2.40 (m, 1 
H, CH2); 3.03 (m, 1 H, CH2); 2.36 (m, 1 H, CH2); 3.70 (m, 1 H, CH2); 4.18 (m, 1 H, 
CH2); 4.44 (m, 1 H, CH); 5.70 (d, 1 H, J = 1.4 Hz, CH); 5.86 (d, 1 H, CH2=); 5.93 (d, 1 
H, CH2=); 6.26 (m, 1 H, CH=); 6.55 (bs, 1 H, CH); 6.58 (d, 1 H, J = 1.4 Hz, CH); 7.79 
(t, 1 H, J = 7.8 Hz, CH); 8.00 (s, 1 H, CH); 8.03 (d, 1 H, J = 8.4 Hz, CH);  8.17 (d, 1 H, 
J = 7.2 Hz, CH); 11.1 (bs, 1 H, COOH). 13C NMR (100 MHz, CDCl3): 20.4(CH3); 
21.1(CH3); 22.6(CH2); 22.9(CH2); 24.4(CH2); 55.6(CH2); 56.2(CH2); 63.4(CH); 
69.3(CH); 70.6(CH); 71.7(CH); 117.1(CHar); 124.9(Car); 125.4(Car); 125.7(CHar); 
126.1(CHar); 128.1(CH2=); 128.1(CHar); 128.8(CH=); 128.8(CF3); 129.7(CF3); 
142.4(Car); 144.4(Car); 165.9 (C=O); 166.6(C=O); 170.8(C=O); 171.4 (C=O). MS: 
[M+H+]=635.3 calculated [M+H+]=634.17+1.01. 
 
 (9S,10R)-N-allyl mefloquine (2a): 
The compound 3a (3.5 g, 5.81 mmol) was dissolved in a mixture of distilled H2O (60 
mL) and DCM (60 mL). The pH was set to 10 with K2CO3 (10% in distilled H2O) and 
the solution was stirred for 16 h. The separated aqueous phase was extracted with 
dichloromethane (2x40 mL). The combined organic solution was dried with MgSO4, 
filtered and evaporated. After purification with column chromatography (CH2Cl2/ 
MeOH; 20:1) (9S, 10R)-N-allyl mefloquine (2a) 2.0 g (82%) was obtained. 
 
 (9R,10S)-N-allyl mefloquine (2b): 
In the similar way, (9R,10S)-N-allyl mefloquine (2b), 1.5 g, (75%) was prepared. 
83 
 
6.1.1 Synthesis of (R,R)-DATAAN (5) 
The (R,R)-tartaric acid (20 g; 133 mmol) was placed in a round bottom flask, which 
was fitted with two reflux condensers and a mechanical stirrer. A solution of 
concentrated H2SO4 (0.6 mL) in acetic anhydride (63 mL) was added and the 
resulting solution was stirred and slowly heated. After the boiling point was reached 
the solution was stirred for further 10 min.  The reaction mixture was cooled down to 
room temperature, transferred into an ice bath cooled Erlenmeyer flask and kept in 
ice for 90 min. The precipitate was filtered and in the inert atmosphere of nitrogen 
washed with benzene (2x20 mL). The product was placed in a round bottom flask 
suspended in dry diethylether (87 mL) and mechanically stirred at 4 °C for 30 min. 
The product was filtered under nitrogen atmosphere and 19.38 g (67%) of compound 
14 were isolated. The product was stored in an evacuated dessicator above P2O5 
and parafine. 
 
6.2 Preparation of carbamates of (9S,10R)- and (9R,10S)-N-allyl 
mefloquine 
 
(9S,10R)-tert-butylcarbamoyl-N-allyl mefloquine (4a): 
N-Allyl mefloquine (2a) (0.5 g; 1.20 mmol) was dissolved in toluene (30 mL). A part of 
the solvent (5 mL) was distilled off and tert-butylisocyanate (0.341 µL; 2.99 mmol) 
and dibutyltin dilaurate as a catalyst (20 µL) were added and the reaction mixture 
was heated to 90 °C for 24 h. The solvent was evaporated and the procedure was 
repeated. The crude product was dissolved in dry toluene (30 mL), from which 5 mL 
was distilled off, and tert-butylisocyanate (136 µL; 1.19 mmol) and the catalyst (20 
µL) were added and the solution was heated up for 2 days. The solvent was removed 
under reduced pressure and the crude product was purified by column 
chromatography (CH2Cl2/MeOH 20:1). It was obtained 0.52 g (84%) of compound 4, 
m.p. 49.5-50.5 °C. 1H NMR (600 MHz, CDCl3):1.13 (m, 2 H, H14a,b); 1.32 (s, 9 H, 
(CH3)3); 1.61 (m, 2 H, H13a,b); 1.72 (m, 2 H, H15a,b); 2,52 (dt, 1 H, H12b, 2J = 11.8 Hz, 3J 
= 3.3 Hz); 2.91 (d, 1 H, H10, 3J = 9.6 Hz); 3.12 (d, 1 H, H12a, 2J = 11.8 Hz); 3.46 (dd, 1 
H, H18b, 2J = 14.2 Hz, 3J = 8.2 Hz); 3.71 (dd, 1 H, H18a, 2J = 14.2 Hz, 3J = 4.1 Hz); 5.4 
(d, 1 H, H20b, 3J = 10.3 Hz); 5.46 (d, 1 H, H20a, 3J = 17.3 Hz); 6.11 (m, 1 H, H19); 6.88 
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(d, 1 H, H9, 3J = 3.6 Hz); 7.93 (t, 1 H, H6, 3J = 8.1 Hz); 7.97 (s, 1 H, H3); 8.30 (d, 1 H, 
H7, 3J = 7.2 Hz); 8.54 (d, 1 H, H5, 3J = 8.5 Hz). 13C NMR (150 MHz, CDCl3): 
C=O(C4); 148.0(C2); 143.9(C8a); 134.5(C19); 129.6(C7); 128.5(C5); 
128.0(C6); 128.4(C17); 127.9(C16); 126.8(C4a); 123.1(C8); 118.7(C20); 115.4(C3); 
69.6(C9); 62.6(C10); 56.9(C18); 53.0(C12); 50.3(C25); 28.0(C26); 24.6(C15); 24.4(C13); 
23.4(C14). 19F NMR (565 MHz, MeOD): -62.10(CF3); -69.97(CF3). MS: [M+H]+ = 
518.0, calculated [M+H]+ = 517.22+1.01. 
Using the same procedure, (9R, 10S)-tert-butylcarbamoyl-N-allyl mefloquine (4b) 
was prepared. It was obtained 0.44 g (71%) of highly viscous oil. 
1H NMR (400 MHz, CDCl3) 1.03 (m, 2 H, CH2); 1.21 (bs, 9 H, (CH3)3); 1.49 (m, 2 H, 
CH2); 1,60 (m, 2 H, CH2); 2.38 (m, 1 H, CH2); 2.77 (m, 1 H, CH2); 3.00 (m, 1 H, CH2,); 
3.33 (m, 1 H, CH); 3.56 (m, 1 H, CH2,); 5.26 (d, 1 H, CH2=CH); 5.32 (d, 1 H, 
CH2=CH); 5.97 (d, 1 H, CH, CH=CH2); 6.75 (d, 1 H, CH, H9); 7.81 (d, 1 H, t, J = 8.3 
Hz, H6); 7.90 (s, 1 H, H3); 8.19 (d, 1 H, J = 7.4 Hz, H7); 8.43 (d, 1 H, J = 7.8 Hz, H5). 
13C NMR (100 MHz, CDCl3) C=O (Car); 148.0 (Car); 143.9 (Car); 136.2 
(CH=CH2); 130.9 (CHar); 129.9 (CHar); 129.3 (CHar); 128.3 (CF3); 126.8 (CF3); 124.1 
(Car); 119.8 (CH2=CH); 118.3 (Car); 116.8 (CHar); 71.2 (CH); 64.0 (CH); 58.3 (CH2); 
54.3 (CH2); 51.7 (Cq); 29.4 (CH3); 25.8 (CH2); 24.9 (CH2); 24.0 (CH2). 19F NMR (375 
MHz, MeOD): -62.10(CF3); -69.97(CF3). MS: [M+H]+ = 518.0, calculated [M+H]+ = 
517.22+1.01. 
 
3,5-bis{trifluoromethyl}phenylcarbamoyl-N-allyl mefloquine (6): 
N-Allyl mefloquine (2b) (0.100 g; .0.24 mmol) was dissolved in dry THF (2 mL) and a 
solution of 3,5-bis{trifluoromethyl}phenyl isocyanate (65.8 mg; 0.26 mmol)  in THF (1 
mL) was added drop wise at 0 °C and the reaction mixture was stirred in the nitrogen 
atmosphere over night. After purification with double column chromatography and 
drying the product for several hours in high vacuum, the compound 31 was obtained 
0.126 mg (78 %), m.p. 47.2-49.3 °C. 1H NMR (400 MHz, MeOD): 1.20 (m, 2 H, CH2); 
1.50 (m, 2 H, CH2); 1.68 (m, 2 H, CH2); 2.35 (dt, 1 H, CH2); 2.89(dt, 1 H, CH); 3.01(dt, 
1 H, CH2); 3.33 (dd, 1 H, CH2); 3.66 (dd, 1 H, CH2);5.17 (d, 1 H, CH2); 5.26 (d, 1 H, 
CH2); 5.82(m, 1 H, CH); 7.06 (d, 1 H, CH); 7.50 (s, 1 H, CH); 7.85 (t, 1 H, CH); 7.94 
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(s, 1 H, CH); 7.99(s, 1 H, CH); 8.22(d, 1 H, CH); 8.52(d, 1 H, CH). 13C NMR (100 
MHz, MeOD): 24.46(CH2); 25.46(CH2); 53.80(CH2-N); 58.51(CH2-N); 64.03(CH-N); 
72.14(CH-O); 114.87(CHar); 116.99(CH=C); 117.43(CHar); 119.74(CHar); 119.28(Car); 
120.19(CHar); 128.32(Car); 129.48(CHar); 129.86(CHar); 131.07(CHar); 133.66(Car); 
134.00 (Car); 136.67 (CHar); 142.55 (Car); 150.84 (C=C); 154.56 (C=O). 19F NMR (375 
MHz, MeOD): -62.10(CF3); -65.30(CF3); -70.02(CF3). MS: [M+H]+ = 674.4 calculated 
[M+H]+= 673.16+1.01 
 
6.3 Immobilization of pure enantiomers of N-allyl mefloquine and its tBu-
carbamates  
 
Immobilization of N-allyl mefloquine (2) 
The selector (0.5 g; 1.19 mmol) and the mercaptopropyl modified silica gel (3 g) were 
placed in a 500 mL three necked round bottom flask. The flask was fitted with a 
mechanical stirrer, a reflux condenser and it was flushed with nitrogen. Methanol (30 
mL) and AIBN (39 mg; 0.24 mmol) were added and the suspension was heated 
under reflux for 18 h. The reaction mixture was cooled down to room temperature 
and filtered. The product was washed with methanol. The chiral stationary phase was 
transferred into a round bottom flask and boiled in methanol. The filtered silica gel 
was dried for 3 h in a drying cabinet (60 °C) and for 12 h in a vacuum drying cabinet 
(60 °C). 
Table 9: The elemental analysis of the N-allyl mefloquine selector (2a: (9S,10R)-N-allyl mefloquine; 2b: (9R,10S)-N-allyl 
mefloquine) 
  
N/g silica 
gel 
C/ g silica 
gel 
   [µmol]  [µmol] 
2b  436  244 
  2b*  72  67 
2a  83  76 
 
The ratio of the coverage calculated for nitrogen and carbon should be in the same 
range. Consequently, the prepared CSP was washed with acidified methanol (10 mL 
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CH3COOH, 40 mL H2O and 50 mL MeOH)  and it was dried for 14 h in the vacuum 
drying cabinet at 60 °C, which afforded CSP 2b*. Despite the coverage of 2a and 2b 
was low, columns were packed. Therefore the sieved silica gel (2 g) was transferred 
in an Erlenmeyer flask. A suspension of acetic acid (1 mL) and isopropanol (20 mL) 
with the silica gel was prepared and sonicated for 10 min. The column was packed in 
house. 
 
Immobilization of tert-butylcarbamoyl-N-allyl mefloquine (4): 
The same procedure as for the immobilization of N-allyl mefloquine (2), described 
above, was employed. The following compounds were used: tert-butylcarbamoyl-N-
allyl mefloquine (4a; 4b) (0.5 g; 0.97 mmol), mercaptopropyl-silica (3 g) and AIBN (32 
mg; 0.19 mmol). 
Table 10: The elemental analysis of 4a: (9S,10R)- t-butylcarbamoyl-N-allyl mefloquine and 4b: (9R,10S)-t-
butylcarbamoyl-N-allyl mefloquine) 
  
N/g silica 
gel 
C/ g silica 
gel 
   [µmol]  [µmol] 
4a  109  113 
4b  133  133 
 
For packing a column of the immobilized selectors 4a,b a suspension of the sieved 
silica (2 g) in acetic acid (1 mL) and isopropanol (20 mL) was prepared. The 
suspension was degassed in an ultrasonic bath and the columns were packed in 
house. 
 
6.4 Analysis of the elution order of N-allyl mefloquine 
 
(O,O)-dibenzoyl-(R,R)-tartaric-N-allyl mefloquine monoester (13) 
A solution of N-allyl mefloquine (2) (0.15 g; 0.36 mmol) and DBTAAN (0.18 g; 0.54 
mmol) in dry dichloromethane (5 mL) was stirred for 18 h under nitrogen atmosphere. 
The solution was extracted with a 5% aqueous NaHCO3 solution (5 mL), 10% 
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aqueous HCOOH (5 mL) and saturated solution of NaCl (2 mL). The organic layer 
was dried with MgSO4 and evaporated. The product was directly used for the HPLC 
measurements. 
 
6.5 Synthesis of analytical probes used for the evaluation of the 
mefloquine-based CSPs 
 
6.5.1 Derivatives of the 4-allyloxy-3,5-dichlorobenzoic acid 
 
Succinimidyl 4-allyloxy-3,5-dichlorobenzoate (14): 
The 4-(allyloxy)-3,5-dichlorobenzoic acid (0.247 g; 1 mmol), hydroxysuccinimide 
(0.126 g; 1.1 mmol), dicyclohexylcarbodiimid (0.237 g; 1.15 mmol) and 
dimethylaminopyridin (50 mg; 0.41 mmol) were dissolved in dry DCM (40 mL) and 
the flask was fitted with a drying tube (CaCl2). The solution was stirred for 4 h at room 
temperature. The precipitated DCU was filtered and the solution was evaporated. 
After column chromatography (PE/EA 1:1) 0.17 g (49%) of the pure compound 14 
was obtained, m.p. 119.2-119.9 °C 
1H NMR (400 MHz, CDCl3): 2.80 (s, 4 H, 2xCH2); 4.60 (d, 2 H, CH2); 5.25 (d, 1 H, 
CH2=CH); 5.35 (d, 1 H, CH2=CH); 6.05 (m, 1 H, CH=CH2); 8.05 (s, 2 H, 2xCHar). 13C 
NMR (100 MHz, CDCl3): 26.1(CH2); 75.2(CH2O); 120.2(CH2=CH); 122.4(Car); 
131.0(Car); 131.6(CHar); 132.6(CH=CH2); 157.1(Car); 160.1(C=O); 169.2(C=O). 
 
N-4-allyloxy-3,5-dichlorobenzoyl L-alanine (15) 
L-Alanine (25.8 mg; 0.29 mmol) and (iPr)2NEt (49.7 µL; 0.29 mmol) were dissolved in 
a diluted aqueous solution of ACN (1:1, 10 mL). The succinimide ester (100 mg; 0.29 
mmol) (22) was added portion wise. The flask was fitted with a reflux condenser and 
the solution was heated to 40 °C over night. The reaction mixture was acidified with 
formic acid (10 µL) and extracted with ethyl acetate (10x20 mL). For transferring the 
product in the organic phase a saturated solution of NaCl (100 mL) was added. The 
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combined organic phases were dried with MgSO4 and evaporated. 0.17 g (49%) of 
the compound 15 was obtained, m.p. 113.6-115.6 °C. 
1H NMR (400 MHz, MeOD): 1.40 (d, 3 H, CH3); 2.55 (s, 1 H, NH); 4.45 (q, 1 H, CH); 
4.55 (d, 2 H, CH2); 5.15 (d, 1 H, CH2=CH); 5.30 (d, 1 H, CH2=CH); 6.05 (m, 1 H, CH); 
7.80 (s, 2 H, 2xCHar). 13C NMR (100 MHz, CDCl3): 17.6(CH3); 50.6(CH-N); 
76.0(CH2O); 119.7(CH2=CH); 129.9(2xCHar); 131.3(Car); 133.0 (Car); 134.6(CH=CH2); 
155.43(Car); 167.2(C=O); 176.3(C=O). 
 
Ammonium trans-2-(N-4-allyloxy-3,5-dichlorobenzoyl)-
aminocyclohexanesulfonate (16)36 
trans-2-Aminocyclohexanesulfonic acid (21 mg; 0.12 mmol) was dissolved in a 
diluted aqueous solution of ACN (1:1, 10 mL). Hünig base (18.8 µL; 0.12 mmol) was 
added and the solution was heated to 40 °C. The ester 14 (40 mg; 0.12 mmol) was 
added portion wise and the reaction was stirred over night. The reaction mixture was 
acidified with formic acid (10 µL) and extracted for several times with ethyl acetate 
(10x20 mL). For better solubility of the product in the organic phase a saturated 
solution of NaCl was added. The combined organic solution was dried with MgSO4, 
filtered and the solvent was evaporated. 0.04 g (85%) of the compound 16 was 
obtained, m.p. 55-62 °C. 
1H NMR (400 MHz, MeOD): 1.20 (m, 3 H, CH2); 1.46 (m, 1 H, CH2); 1.69 (m, 2 H, 
CH2); 2.12 (m, 1 H, CH2);  2.28 (m, 1 H, CH2); 2.66 (dt, 1 H, CH); 3.95 (dt, 1 H, CH); 
4.49 (d, 2 H, CH2); 5.16 (m, 1 H, CH2=CH); 5.31 (m, 1 H, CH2=CH); 6.02 (m, 1 H, 
CH=CH2); 7.78 (s, 2 H, 2xCHar). 
 
6.5.2 Derivatives of the 3,4,5-trimethoxybenzoic acid 
 
Succinimidyl 3,4,5-trimethoxybenzoate (18) 
Trimethoxybenzoic acid (2 g; 9.4 mmol), hydroxysuccinimide (1.19 g; 10.3 mmol), 
dicyclohexylcarbodiimide (2.2 g; 10.8 mmol) and dimethylaminopyridine (70 mg) 
were dissolved in dry DCM (50 mL) and stirred for 5 h without presence of air 
moisture (CaCl2 drying tube). The precipitated dicyclohexylurea was filtered and the 
89 
 
filtrate was evaporated. The crude product was purified by column chromatography. 
It was obtained 2.5 g (87%) of active ester 18, m.p. 130.4-131.8 °C. 
1H NMR (400 MHz, CDCl3): 2.84 (s, 4 H, 2xCH2); 3.82 (s, 6 H, 2xCH3); 3.85 (s, 3 H, 
CH3); 7.29 (s, 2 H, 2xCHar). 13C NMR (100 MHz, CDCl3): 25.2(CH2); 56.8 (CH3); 61.6 
(CH3); 108.34 (CHar); 120.0(Car); 144.5(Car); 153.6 (Car); 161.9 (C=O); 169.5 (C=O). 
 
N-3,4,5-trimethoxybenzoyl L-alanine (19a) 
The same procedure as for the derivatization of the 4-(allyloxy)-3,5-dichlorobenzoyl 
succinimide ester (22) with L-alanine, described in section 5.4.1, was employed. The 
following compounds were used: succinimidyl trimethoxybenzoate 18 (50 mg; 0.16 
mmol), L- alanine (14.4 mg; 0.16 mmol) and (iPr)2NEt (27.7 µL ; 0.16 mmol). It was 
obtained 42 mg (81%) of the derivative 19a, m.p. 107.6-109.8 °C. 
1H NMR (400 MHz, CDCl3): 1.49 (d, 3 H, CH3); 3.80 (s, 3 H, OCH3); 3.82 (s, 6 H, 
2xOCH3); 4.69 (m, 1 H, CH); 6.98 (s, 2 H, 2xCHar). 13C NMR (100 MHz, CDCl3): 
18.8(CH3); 49.4(CH); 56.7(OCH3); 61.6(OCH3); 105.1(CHar); 129.03(Car); 141.8(Car); 
153.4(Car); 172.7(C=O); 176.3(C=O). 
 
N-3,4,5-trimethoxybenzoyl D/L-alanine (19b) 
The racemic compound 19b was obtained in the same way as the enantiomerically 
pure selectand 19a. 
 
N-3,4,5-trimethoxybenzoyl L-leucine (20a) 
A solution of L-leucine (0.127 g; 0.97 mmol) and (iPr)2NEt (166 µL, 0.97 mmol) in 
aqueous ACN (1:1, 10 mL) was warmed up to 40 °C, and the flask was fitted with a 
reflux condenser. The active ester 18 (0.3 g; 0.97 mmol) was added portion wise, 
and the reaction mixture was stirred and heated over night. The solution was 
acidified with formic acid (10 µL), diluted with a saturated solution of NaCl (100 mL) 
and extracted with ethyl acetate (15x30 mL). The combined organic solution was 
dried with MgSO4, filtered and evaporated. The crude product was purified by column 
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chromatography (PE/EA, 1:2). It was obtained 0.19 g (60%) of compound 20a, m.p. 
80.6-81.7 °C. 
1H NMR (400 MHz, MeOD): 1.0 (dd, 6 H, 2xCH3); 1.79 (m, 3 H, CH, CH2); 2.7 (s, 1 H, 
NH); 3.82 (s, 3 H, OCH3); 3.9 (s, 6 H, 2xOCH3); 4.64 (m, 1 H, CH); 7.22 (s, 2 H, 
2xCHar). 13C NMR (100 MHz, MeOD): 22.2(CH3); 26.7(CH); 41.8(CH2); 53.2(CH); 
57.2(CH3); 61.5(CH3); 106.7(CHar); 131.0(Car); 142.6(Car); 154.8(Car); 170.2(C=O); 
176.7(C=O).  
 
N-3,4,5-trimethoxybenzoyl D-leucine (20b) 
The analogic procedure was utilized for the derivatization of the succinimidyl 3,4,5-
trimethoxybenzoate (18) with D-leucine. The following compounds were used: D-
leucine (72.1 mg; 0.54 mmol), trimethoxybenzoic acid succinimide ester (0.170 g; 
0.54 mmol) and (iPr)2NEt (94 µL, 0.54 mmol). It was obtained 50 mg (66%) of the 
compound 20b. 
1H NMR (400 MHz, MeOD): 0.89 (dd, 6 H, 2xCH3); 1.65 (m, 1 H, CH); 1.73 (m, 2 H, 
CH2); 3.72 (s, 3 H, OCH3); 3.79 (s, 6 H, 2xOCH3); 4.6 (m, 1 H, CH); 7.1 (s, 2 H, 
2xCHar). 13C NMR (100 MHz, MeOD): 22.2(CH3); 26.7(CH); 35.2(CH2); 53.2(CH); 
57.1(CH3); 61.6(CH3); 106.7(CHar); 130.9(Car); 142.7(Car); 154.8(Car); 170.0(C=O); 
176.9(C=O). 
 
6.5.3 Derivatives of the pentafluorobenzoic acid 
 
Succinimidyl 2,3,4,5,6-pentafluorobenzoate (22) 
Pentafluorobenzoic acid (1.50 g; 7.07 mmol), hydroxysuccinimide (0.90 g; 7.78 
mmol), dicyclohexylcarbodiimide (1.68 g; 8.14 mmol) and dimethylaminopyridine (40 
mg; 0.40 mmol) were placed in round bottom flask, dissolved in dry DCM (30 mL) 
and stirred for 6 h. The precipitated DCU was filtered and the filtrate was partially 
removed under reduced pressure. The crude product was purified by column 
chromatography (PE/ EA, 1:2). It was obtained 1.25 g (57%) of ester 22, m.p. 101.8-
102.3 °C. 
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1H NMR (400 MHz, CDCl3): 2.82 (s, 4 H, 2xCH2). 13C NMR (100 MHz, CDCl3): 26.0 
(CH2); 168.5 (C=O). 19F NMR (375 MHz, CDCl3): -159.19 (meta-F); -143.48(para-F); 
-133.17(ortho-F). 
 
N-2,3,4,5,6-pentafluorobenzoyl D-leucine (23a)  
D-leucine (0.13 g; 0.97 mmol) was dissolved in a diluted aqueous solution of ACN 
(1:1, 20 mL). (iPr)2NEt (0.17 mL; 0.97 mmol) and the active ester 22 (0.30 g; 0.97 
mmol) were added. The reaction mixture was stirred and heated to 40 °C over night. 
The solution was acidified with formic acid (10 µL), diluted with a saturated solution of 
NaCl (100 mL) and extracted with ethyl acetate (10x20 mL). The combined organic 
layers were dried with MgSO4, filtered and evaporated. The crude product (23a) was 
purified by double column chromatography (1st: PE/ EA , 1:2; 2nd: CH2Cl2/MeOH, 
5:1). It was obtained 0.21 g (66%) of amide 23a, m.p. 169.7-172.4 °C. 
1H NMR (400 MHz, MeOD): 1.00 (m, 6 H, 2xCH3); 1.70 (m, 1 H, CH); 1.75 (m, 2 H, 
CH2); 2.65 (s, 1 H, NH); 4.60 (m,1 H, CH). 13C NMR (100 MHz, MeOD): 22.06(CH3); 
23.81(CH3); 26.48(CH); 26.69(CH2); 53.52(CH); 171.8(C=O); 177.6(C=O). 19F NMR 
(375 MHz, MeOD): -143.9 (ortho-F); -156.0 (para-F); -164.6 (meta-F). 
 
N-2,3,4,5,6-pentafluorobenzoyl L-leucine (23b)  
The same procedure (see above) was employed for the synthesis of N-2,3,4,5,6-
pentafluorobenzoyl L-leucine (23b). Following amounts were used: L-leucine (0.09 
mg, 0.68 mmol), pentafluorobenzoic acid succinimide ester (22) (0.21 g; 0.68 mmol) 
and (iPr)2NEt (116 µL; 0.68 mmol ). It was obtained 0.16 g (70%). 
1H NMR (400 MHz, MeOD): 0.89 (d, 6 H, 2xCH3); 1.27 (m, 2 H, CH2); 1.62 (m, 1 H, 
CH); 4.50 (m, 1 H, CH). 13C NMR (100 MHz, MeOD): 22.13(CH3); 23.86(CH3); 
26.50(CH); 26.68(CH2); 53.96(CH); 170.9(C=O); 176.4(C=O). 19F NMR (375 MHz, 
MeOD): -143.91(ortho-F); -156.19(para-F); -164.62(meta-F). 
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6.6 Synthesis of a strong cation exchanger based on 4-allyloxy-3,5-
dimethoxybenzoic acid 
 
Allyl-4-allyloxy-3,5-dimethoxybenzoate (24): 
To a suspension of syringic acid (5.0 g; 25.2 mmol) and K2CO3 (8.7 g; 63.0 mmol) in 
dry DMF (60 mL), allyl bromide (5.5 mL; 63.0 mmol) was added. The reaction mixture 
was stirred and heated to 60 °C over night and then decomposed with distilled water 
(200 mL). The brown solution was extracted with ethyl acetate (5x100 mL). The 
combined organic layers were washed with a saturated solution of NaCl, dried with 
MgSO4, filtered and evaporated. In order to remove the rest of DMF toluene was 
added for several times to the brown liquid (24) and re-evaporated. It was obtained 
6.54 g (93%) of compound 24, which was directly used in the subsequent hydrolysis. 
In this case we used only TLC characterization of the product. 
 
4-allyloxy-3,5-dimethoxybenzoic acid (Allyloxy syringic acid) (25): 
The compound 24 (6.54 g; 23.5 mmol) was dissolved in a mixture of 1.4 M NaOH 
solution (2.8 g; 70 mmol, 50 mL) and ethanol (50 mL). The reddish solution was 
refluxed for 90 min. Then the flask was cooled with an ice bath and the solution was 
acidified with a diluted HCl solution (1:1); the pH was set to 3. The precipitate was 
filtered and washed with distilled water. 4.08 g (73%) of the allyloxy syringic acid 25 
were obtained, m.p.111.2-113.4 °C.  
 1H NMR (400 MHz, MeOD): 3.90 (s, 6 H, 2xOCH3); 4.50 (d, 2 H, CH2); 5.15 (d, 1 H, 
CH2=CH); 5.3 (d, 1 H, CH2=CH); 6.05 (m, 1 H, CH=CH2); 7.35 (s, 2 H, 2xCHar). 13C 
NMR (100 MHz, MeOD): 57.0(OCH3); 75.5(CH2); 108.6(CHar); 118.5(CH2); 
127.6(Car); 136.0(CH); 142.4(Car); 155.0(Car); 169.8(C=O). 
 
Succinimidyl 4-allyloxy-3,5-dimethoxy benzoate (Allyloxy syringic succinimide 
ester) (26): 
The same procedure as for the synthesis of the succinimide ester of the 3,4,5-
trimethoxybenzoic acid, described in section 5.4.2, was employed. The following 
compounds were used: allyloxy syringic acid (25) (1 g; 4.20 mmol), 
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hydroxysuccinimide (0.53 g; 4.61 mmol), dicyclohexylcarbodiimide (1 g; 4.82 mmol) 
and dimethylaminopyridine (60 mg). It was obtained 0.70 g (50%) of allyloxy syringic 
succinimide ester 26, m.p. 131.7-134.5 °C. 
1H NMR (400 MHz, CDCl3): 2.82 (s, 4 H, CH2); 3.82 (s, 6 H, 2xOCH3); 4.55 (d, 2 H, 
CH2); 5.11 (d, 1 H, CH2=CH); 5.21 (d, 1 H, CH2=CH); 5.99 (m, 1 H; CH=CH2); 7.3 (s, 
2 H, 2xCHar). 13C NMR (100 MHz, CDCl3): 25.2(CH2); 56.7(CH3); 74.6(CH2); 
108.2(CHar); 118.9(CH2); 120.0(Car); 134.1(CH); 153.9(Car); 162.0(C=O); 
169.7(C=O). 
 
Ammonium trans-2-(N-(4-allyloxy-3,5-dimethoxybenzoyl)-aminocyclohexane-
sulfonate (27): 
The same procedure as in case of the derivatization of the 4-(allyloxy)-3,5-
dichlorobenzoic succinimide ester 14 with trans-2-aminocyclohexansulfonic acid, 
described in section 5.4.1, was utilized. The following compounds were used: allyloxy 
syringic succinimide ester (0.82 g; 2.44 mmol), trans-2-aminocyclohexanesulfonic 
acid (0.44 g; 2.44 mmol) and (iPr)2NEt (0.42 mL; 2.44 mmol). 
It was not possible to extract the product from the aqueous solution. Therefore a 
continuous extraction was performed and the aqueous solution was washed with 
chloroform for 2 days. The layers were separated and the organic solution was dried 
with MgSO4 and filtered. The solvent was removed under reduced pressure and the 
pure enantiomers were obtained by preparative separation on HPLC (stationary 
phase: QD-AX (250x20 mm, 10 µm), mobile phase: MeOH, 0.5% HCOOH and 0.5% 
NH4OOCH). After evaporation of the mobile phase and sublimation of the formic acid, 
the pure compounds 27a (0.44 g; 45%) and 9b (0.44 g; 45%) were obtained. 
(R,R): m.p. 146.3-148.6 °C. 
1H NMR (400 MHz, MeOD): 1.26(m, 2 H, CH2); 1.50 (m, 2 H, CH2); 1.70 (m, 2 H, 
CH2) 2.28 (m, 2 H, CH2); 2.79 (dt, 1 H ,CH); 3.75 (s, 6 H, 2xOCH3); 3.86 (dt, 1 H, 
CH); 4.38 (d, 2 H, CH2); 5.05 (m, 1 H, CH2=CH); 5.16 (m, 1 H, CH2=CH); 5.93 (m, 1 
H, CH=CH2); 7.09 (s, 2 H, 2xCHar). 13C NMR (100 MHz, MeOD): 26.2(CH2); 
26.8(CH2); 29.8(CH2); 34.2(CH2); 53.5(CH); 57.1(CH3); 63.1(CH); 75.4(CH2); 
106.4(CHar); 118.5(CH2); 132.4(Car); 136.0(CH); 140.7(Car); 155.0(Car); 169.4(C=O). 
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Immobilization of the ammonium trans-2-(N-allyloxy-syringic acid)-
aminocyclohexanesulfonate (27) 
The mercaptopropyl modified silica gel (2.5 g) was placed in a three necked round 
bottom flask, which was fitted with a mechanical stirrer and a reflux condenser and 
the apparatus was flushed with nitrogen. The compound 27 (0.45 g; 1.13 mmol) was 
dissolved in methanol and poured in the three necked flask. A solution of AIBN (50 
mg; 0.30 mmol) in methanol (3 mL) was added and the reaction mixture was heated 
under reflux for 8 h in the inert atmosphere of nitrogen. The reaction mixture was 
cooled down to room temperature. The CSP was filtered and washed with methanol 
(3x10 mL) and CH2Cl2 (2x15 mL). The product was dried for 3 h in a drying cabinet 
(60 °C) and for 12 h in a vacuum drying cabinet (60 °C). The coverage was 182 
µmol/ g S. 
Table 11: Coverage of the novel SCXs immobilized on mercaptoporpyl silica gel 
  S/g silica
  [µmol]
27a 182
27b 202 
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8. Attachments 
 
Abstract 
 
In the last decades chromatographic enantioseparation with chiral stationary phases 
(CSPs) has become a widely used analytical and industrial tool, mainly because of 
the importance of enantioseparation in the drug development.  
The aim of the presented thesis was to synthesize novel selectors based on 
mefloquine and to evaluate their potential as a new anion exchange type of chiral 
stationary phases. In the design of the novel selector we were inspired by a 
commercially available QN-AX and QD-AX CSP respectively, which were developed 
in our working group. We assumed that a π-acidic quinoline unit of mefloquine (in 
contrast to a π-basic core of quinine) would lead to an altered separation of π-basic 
analytes. 
We synthesized several different enantiomerically pure selectors based on N-allyl 
mefloquine and immobilized some of them on mercaptopropyl modified silica gel. The 
structural resemblance of mefloquine to chinchona alkaloids (quinine, quinidine) 
allowed us to determine the elution order of N-allyl mefloquine enantiomers. The 
absolute configuration of (9R,10S)-N-allyl mefloquine was verified by the x-ray 
analysis. 
In order to evaluate the prepared CSPs based on mefloquine, several new π-basic 
and fluorophilic leucine derivatives were prepared. These selectands (SAs) were 
further used for NMR studies with selected selectors. Corresponding to the NMR 
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studies, we found out that the mefloquine selectors interact with selected leucine 
analytes in a similar way as the chinchona based selectors. We have not found any 
additional fluorophilic interactions for N-allyl mefloquine with polyfluorinated analytes, 
which could be considered as a drawback of the new selectors. 
We found that N-allyl mefloquine derivatives and mefloquine itself can be effectively 
separated on strong cation exchanger columns. Therefore we developed a novel 
strong cation exchanger based on O-allyl syringic acid with trans-2-
aminocyclohexanesulfonic acid. We proved that the separation of several types of 
mefloquine-based compounds was better with our new SCX CSPs.  
Furthermore, we discovered during the evaluation of the novel SCX CSPs that a 
selector based on mefloquine with non-derivatized nitrogen in the piperidine moiety 
will be more efficiently enantioseperated, which was also non expected. 
To conclude, we designed and synthesized several novel chiral selectors based on 
mefloquine and evaluated the applicability in enantioseparation using NMR and 
HPLC methods. In addition we developed novel SCX chiral stationary phases, which 
can be used for enantioseparation of mefloquine derivatives and chiral amines in 
general. 
 
 Zusammenfassung 
 
Die Trennung von Racematen in ihre Enantiomere mittels chiralen stationären 
Phasen nahm sowohl in der Analytischen Chemie als auch in der Industrie in den 
letzten Jahrzehnten an Bedeutung zu. Nicht zuletzt wegen der Notwendigkeit 
enantiomerenreine Medikamente, die die gewünschte Wirkung erzielen, zu 
produzieren.  
Die Synthese von neuen Selektoren basierend auf Mefloquin als auch die 
Evaluierung von chiralen stationären Phasen immobilisiert mit Mefloquinderivaten, 
waren Ziele der vorliegenden Diplomarbeit. Die Anionenaustauscher stationären 
Phasen basierend auf Chinchona Alkoloiden (Chinin und Chinidin), entwickelt in 
unserer Arbeitsgruppe, waren Motivation für die Entwicklung von auf Mefloquin 
beruhenden stationären Phasen. Mefloquin sollte aufgrund der vermuteten π-sauren 
Natur der Chinolin-Einheit für die Enantiomerentrennung von π-basischen Analyten 
geeignet sein.  
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Wir synthetisierten verschiedene enantiomerenreine  N-allyl Mefloquinderivate. 
Ausgewählte Derivate wurden als Selektoren auf modifiziertem Kieselgel 
immobilisiert, um neue chirale stationäre Phasen zu erhalten. 
Die strukturelle Ähnlichkeit von Mefloquin und den Chinchona Alkaloiden 
ermöglichte, durch Vergleich der Elutionsreihenfolge der entsprechenden 
Weinsäureester, die Bestimmung der Elutionsreihenfolge von den erythro 
Enantiomeren des N-allyl Mefloquins. Zusätzlich konnte die Absolutkonfiguration des 
(9S,10R)-N-allyl Mefloquins mittels Röntgenstrukturanalyse bestimmt werden, womit 
unser chromatographischer Ansatz bestätigt wurde. 
Für die Evaluierung der neuen stationären Phasen wurden π-basische als auch 
polyfluorierte Analyte synthetisiert. Des Weiteren wurden diese Selektanden auch für 
NMR Studien mit ausgewählten Selektoren verwendet. Die NMR Studien ergaben, 
dass Mefloquinderivate und Chinidin in vergleichbarer Weise mit Selektanden 
interagieren. Es konnten allerdings keine zusätzlichen Fluor-Wechselwirkungen 
zwischen Mefloquin und polyfluorierten Analyten beobachtet werden.  
Eine effiziente Trennung der Mefloquinderivate wurde mittels eines 
Kationenaustauschers als chirale stationäre Phase erreicht. Aufgrund dessen, 
entwickelten wir neue Kationenaustauscher-Säulen basierend auf Syringasäure. Die 
Evaluierung der neuen Kationenaustauscher-Säulen ergab eine bessere 
Enantiomerentrennung für Mefloquinderivate im Vergleich zu einer in unserer 
Arbeitsgruppe etablierten Kationenaustauscher-Säule. Des Weiteren ergab die 
Evaluierung der neuen Kationenaustauscher-Säulen, dass ein Selektor basierend auf 
Mefloquin effizienter in seine Enantiomere getrennt werden kann, wenn der Stickstoff 
des Piperidins als sekundäres Amin, wie eben im Mefloquin, vorliegt.  
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